|
ABCB1
|
COAD
|
multidrug-resistance, efflux-pump, pharmacogenomics
|
|
ABCB11
|
HCC
|
|
|
ABCC2
|
MEL
|
transporter, transcriptomic-marker
|
|
ABL1
|
AML
|
gene-fusion, tyrosine-kinase
|
|
ACADL
|
MNG
|
metabolic, ihc-marker, meningioma
|
|
ACTA2
|
GBC
|
CAF, EMT, stromal
|
|
ACTB
|
DLBCL
|
cytoskeleton, somatic-mutation
|
|
ACTG1
|
PRCC
|
gene-fusion, MiTF-family, kidney-cancer
|
|
ACTN4
|
ADCC
|
|
|
ACVR1B
|
ADCC
|
|
|
ACVR1C
|
|
|
|
ACVR2A
|
COAD
|
tumor-suppressor, TGF-beta, hypermutated, mismatch-repair-deficient
|
|
ADAM2
|
ACYC
|
axon-guidance, salivary-gland
|
|
ADAMTS13
|
ACYC
|
axon-guidance, salivary-gland
|
|
ADAMTS5
|
ACYC
|
axon-guidance, salivary-gland
|
|
ADCY2
|
ALM
|
|
|
ADORA2A
|
NPC
|
adenosine-receptor, immunotherapy, checkpoint, tumor-microenvironment
|
|
AFDN
|
BRCA
|
tumor-suppressor, cell-adhesion, tissue-organisation
|
|
AGAP3
|
CRC
|
|
|
AGK
|
|
fusion-partner, braf-fusion, kinase
|
|
AGTR2
|
BRCA
|
receptor, gpcr, therapeutic-target
|
|
AHNAK2
|
BRCA
|
high-background-mutation-rate, uncertain-driver
|
|
AHR
|
|
transcription-factor, pharmacogenomics, MEK-inhibitor-sensitivity
|
|
AIG1
|
|
|
|
AJAP1
|
ESCA
|
tumor-suppressor-candidate, chromatin-remodeling
|
|
AJUBA
|
CSCC
|
tumor-suppressor, skin-cancer
|
|
AKAP6
|
ESCA
|
tumor-suppressor-candidate
|
|
AKAP9
|
STAD
|
|
|
AKT1
|
BLCA, UTUC
|
pi3k-pathway, oncogene, resistance
|
|
AKT2
|
UCEC
|
pi3k-pathway, oncogene, amplification
|
|
AKT3
|
BRCA
|
PI3K-AKT-pathway, fusion, triple-negative-breast-cancer, kinase
|
|
ALB
|
HCC
|
liver, somatic-mutation, non-actionable
|
|
ALDH1A1
|
GBC
|
EMT, stemness, cancer-stem-cell
|
|
ALDH1L2
|
SKCM
|
metabolism, folate-cycle, ipres
|
|
ALDOC
|
ODG
|
astrocytic-marker, oligodendroglioma, differentiation
|
|
ALK
|
LCH, ECD, NSCLC, NBL
|
fusion, kinase, histiocytosis, neuroblastoma
|
|
ALKBH5
|
ICCA
|
|
|
ALMS1
|
SCLC
|
centrosome, sclc, significantly-mutated-gene
|
|
AMER1
|
COAD
|
tumor-suppressor, WNT-pathway, X-linked
|
|
ANKRD36
|
|
|
|
ANKRD62
|
BLCA
|
ankyrin-repeat, urothelial, clonal-evolution
|
|
APC
|
HCC
|
tumor-suppressor, wnt-pathway, truncating
|
|
APEX1
|
PRCC
|
DNA-repair, MiTF-family, kidney-cancer
|
|
APOB
|
HCC
|
liver, somatic-mutation, non-actionable, lipid-metabolism
|
|
APOBEC3A
|
BLCA
|
mutational-signature, cytidine-deaminase, apobec, chemotherapy-resistance
|
|
APOBEC3B
|
BLCA
|
mutational-signature, cytidine-deaminase
|
|
APOE
|
ODG
|
astrocytic-marker, oligodendroglioma, differentiation, lipid-metabolism
|
|
AR
|
PRAD
|
hormone-receptor, oncogene, neuroendocrine
|
|
ARAF
|
ACBC, BRCA
|
mapk-pathway, adenoid-cystic-carcinoma, subclonal-mutation, raf-kinase
|
|
ARHGAP26
|
STAD
|
fusion, GS-subtype, RHO-pathway
|
|
ARHGAP35
|
LUAD
|
ras-pathway, rho-gap, tumor-suppressor
|
|
ARHGAP6
|
STAD
|
fusion, GS-subtype, RHO-pathway
|
|
ARHGEF18
|
ACYC
|
Rho-pathway, salivary-gland
|
|
ARHGEF3
|
ACYC
|
Rho-pathway, salivary-gland
|
|
ARHGEF5
|
ACYC
|
Rho-pathway, salivary-gland
|
|
ARID1A
|
CLLSLL, LUAD, NSCLC
|
swi-snf, chromatin-remodeling, driver
|
|
ARID1B
|
SCLC
|
chromatin-remodeling, SWI-SNF, tumor-suppressor
|
|
ARID2
|
MEL, CSCC, UCEC
|
swi-snf, chromatin-remodeling, tumor-suppressor
|
|
ARID4A
|
BLCA
|
chromatin-remodeling
|
|
ARID5B
|
UCEC
|
chromatin-remodeling, swi-snf, tumor-suppressor-candidate
|
|
ASCC2
|
|
|
|
ASCL1
|
ODG
|
proneural-transcription-factor, stem-progenitor, oligodendroglioma, neural-differentiation
|
|
ASCL4
|
LUSC
|
|
|
ASH2L
|
PRAD
|
chromatin-remodeling, MLL-complex, AR-signaling, histone-methylation
|
|
ASNS
|
UCEC
|
metabolism, rppa
|
|
ASPM
|
SCLC
|
centrosome, sclc, significantly-mutated-gene
|
|
ASPSCR1
|
TRCC
|
gene-fusion, TFE3, kidney-cancer
|
|
ASXL1
|
CLLSLL
|
epigenetic, prognostic, u-cll
|
|
ASXL2
|
BLCA
|
chromatin-modifier, polycomb, tumor-suppressor
|
|
ASXL3
|
NBL
|
chromatin-regulator, neuroblastoma, progenitor-program
|
|
ATF1
|
|
|
|
ATM
|
CLLSLL, ANGS
|
dna-damage-response, driver
|
|
ATP8B2
|
|
|
|
ATR
|
THPA
|
dna-damage-response, replication-stress, kinase
|
|
ATRX
|
AST, DIFG, ANGS, LMS
|
chromatin-remodeler, alt, astrocytoma
|
|
ATXN1
|
|
|
|
AURKA
|
PRAD
|
kinase, neuroendocrine, mycn-axis
|
|
AURKB
|
BRCA
|
mitosis, kinase, cell-cycle
|
|
AURKC
|
OCSC, HNSC
|
kinase, therapeutic-target
|
|
AXIN1
|
|
|
|
AXIN2
|
|
|
|
AXL
|
MEL
|
receptor-tyrosine-kinase, melanocyte-state, invasive-phenotype
|
|
B2M
|
CHL
|
immune-escape, mhc-class-i, early-event
|
|
BANF1
|
OVT
|
micronuclei, cgas-sting, innate-immunity
|
|
BAP1
|
PLMESO, RMS
|
tumor-suppressor, chromatin-remodeling, deubiquitinase
|
|
BARD1
|
NBL
|
dna-repair, brca1-complex
|
|
BAZ1A
|
UCS, MXOV
|
chromatin-remodeling, SWI-SNF, carcinosarcoma
|
|
BAZ2B
|
CLLSLL
|
|
|
BBC3
|
NPC
|
apoptosis, pro-apoptotic, EBV, microRNA
|
|
BCL10
|
DLBCL, FL
|
NF-kB, lymphoma, oncogene
|
|
BCL11A
|
NBL
|
transcription-factor, neuroblastoma, progenitor-program, chromatin-regulator
|
|
BCL11B
|
|
|
|
BCL2
|
CLLSLL, DLBCLNOS
|
translocation, apoptosis, m-cll
|
|
BCL2L1
|
LUSC
|
|
|
BCL2L11
|
UCEC
|
apoptosis, bcl-family, gene-fusion
|
|
BCL6
|
DLBCLNOS
|
translocation, transcription-factor, lymphoma
|
|
BCL7A
|
CHL
|
early-event, aid-target
|
|
BCL9
|
UCEC
|
wnt-pathway, bcl-family, gene-fusion
|
|
BCL9L
|
COAD, READ
|
wnt-pathway, co-factor, driver
|
|
BCLAF1
|
|
|
|
BCOR
|
RMS
|
tumor-suppressor, chromatin-remodeling, rhabdomyosarcoma
|
|
BCR
|
AML
|
gene-fusion, tyrosine-kinase
|
|
BEND2
|
SARC
|
|
|
BICC1
|
|
|
|
BIRC2
|
OCSC, HNSC
|
apoptosis, iap-family, amplification
|
|
BIRC3
|
OCSC, HNSC
|
apoptosis, iap-family, amplification
|
|
BIRC7
|
PRCC, TRCC
|
MiTF-family, kidney-cancer, therapeutic-target, apoptosis
|
|
BLK
|
PCM
|
|
|
BLM
|
|
dna-damage-response, helicase, bloom-syndrome
|
|
BMP4
|
MRT, MRTL
|
BMP-signaling, developmental, rhabdoid-tumor
|
|
BMPR1A
|
STAD
|
hereditary-cancer, gastric-cancer, juvenile-polyposis, germline, TGF-beta
|
|
BOC
|
ODG
|
stem-progenitor, oligodendroglioma, hedgehog-signaling, cell-adhesion
|
|
BRAF
|
CLLSLL, LCH, ECD, MEL, DIFG, NSCLC, THPA
|
kinase, mapk, actionable
|
|
BRCA1
|
OVT, UCEC, CESC, THPA, PRAD, NBL, HGSOC
|
dna-damage-response, homologous-recombination, germline, tumor-suppressor
|
|
BRCA2
|
OVT, UCEC, CESC, THPA, HCC, PRAD, NBL, HGSOC
|
dna-damage-response, homologous-recombination, germline, tumor-suppressor
|
|
BRCC3
|
CLLSLL
|
|
|
BRD2
|
|
|
|
BRD3
|
LUAD
|
|
|
BRD4
|
SCLC
|
BET-bromodomain, chromatin-remodeling, therapeutic-target, synthetic-lethality
|
|
BRD7
|
CCRCC
|
|
|
BRD9
|
CLLSLL
|
bromodomain, splicing-factor-target, sf3b1, uveal-melanoma
|
|
BRIP1
|
|
|
|
BRPF1
|
|
|
|
BST2
|
ESCC
|
|
|
BTG1
|
DLBCL, FL
|
apoptosis, lymphoma, tumor-suppressor
|
|
BTG2
|
BLCA
|
|
|
BTK
|
DLBCLNOS
|
kinase, B-cell-signaling, NF-kB, driver
|
|
BTLA
|
NPC
|
checkpoint, T-cell-exhaustion, immunotherapy, tumor-microenvironment
|
|
BUB1
|
BRCA
|
mitosis, spindle-assembly-checkpoint, cell-cycle
|
|
BUB1B
|
RMS
|
mitotic-checkpoint
|
|
C19ORF38
|
ULM
|
hmga-target, biomarker, expression
|
|
C1QA
|
|
|
|
C2CD4C
|
ROCY
|
kidney-cancer, significantly-mutated-gene, uncharacterized
|
|
CACNA1A
|
RMS
|
|
|
CACNA1D
|
STAD
|
|
|
CACNG6
|
DIFG, GBM, ASTR, ODG
|
promoter-mutation, glioma, downregulation
|
|
CADM2
|
|
|
|
CALR
|
|
|
|
CANX
|
CRC
|
antigen-presentation, immune-evasion, MHC-class-I
|
|
CAPZA2
|
LUAD
|
fusion-gene, MET-fusion, lung-adenocarcinoma
|
|
CARD11
|
PCNSL, DLBCLNOS
|
bcr-pathway, ibrutinib-resistance
|
|
CASP1
|
HCC
|
apoptosis, caspase, pyroptosis
|
|
CASP8
|
HNSC
|
apoptosis, somatic-mutation, whole-exome-sequencing
|
|
CBFA2T3
|
AMKL
|
|
|
CBFB
|
BRCA
|
transcription-factor, differentiation, ER-positive, tumor-suppressor
|
|
CBL
|
CSCC
|
|
|
CCDC149
|
THPD
|
fusion, ALK-fusion, thyroid-cancer, novel-fusion-partner
|
|
CCDC6
|
THPD, THAP
|
fusion, RET-fusion, thyroid-cancer
|
|
CCDC74A
|
|
|
|
CCL13
|
SKCM
|
chemokine, immune-resistance, IPRES, anti-PD-1
|
|
CCL2
|
SKCM
|
chemokine, immune-resistance, IPRES, anti-PD-1
|
|
CCL5
|
COAD
|
chemokine, icr-signature, immune-infiltration
|
|
CCL7
|
SKCM
|
chemokine, immune-resistance, IPRES, anti-PD-1
|
|
CCL8
|
SKCM
|
chemokine, immune-resistance, IPRES, anti-PD-1
|
|
CCN2
|
GBC
|
CAF, stromal, fibrosis
|
|
CCNB1
|
|
|
|
CCND1
|
EGC, STAD, ESCA, GEJ, ODG, ACRM
|
|
|
CCND2
|
ODG
|
cell-cycle, stem-progenitor, oligodendroglioma, cyclin
|
|
CCND3
|
PTAD, ODG
|
|
|
CCNE1
|
UCEC, UCS, USC, EGC, STAD, ESCA, GEJ, HGSOC
|
|
|
CCNE2
|
GBM
|
amplification, cell-cycle
|
|
CD24
|
ODG
|
stem-progenitor, oligodendroglioma, cell-surface-marker, neural-progenitor
|
|
CD247
|
SKCM
|
TCR-signaling, immune-checkpoint, T-cell, co-stimulation
|
|
CD274
|
COAD, HNSC
|
immune-checkpoint, icr-signature, counter-regulation, pd-l1
|
|
CD276
|
NPC
|
checkpoint, immunotherapy, ADC, tumor-microenvironment
|
|
CD28
|
SKCM
|
T-cell, co-stimulation, TCR-signaling, immune-checkpoint
|
|
CD3D
|
SKCM
|
TCR-complex, T-cell, immune-checkpoint, co-stimulation
|
|
CD3E
|
SKCM
|
TCR-complex, T-cell, immune-checkpoint, co-stimulation
|
|
CD3G
|
SKCM
|
TCR-complex, T-cell, immune-checkpoint, co-stimulation
|
|
CD4
|
HNSC
|
t-cell, immune-biomarker, peripheral-blood, checkpoint-immunotherapy
|
|
CD44
|
GBC, STAD
|
EMT, stemness, cancer-stem-cell, amplification
|
|
CD5
|
CLLSLL
|
cll-marker, b-cell, mRNA-upregulation, sf3b1
|
|
CD58
|
DLBCL
|
immune-evasion, somatic-mutation
|
|
CD70
|
NPC
|
TNF-ligand, Treg, immunotherapy, ADC, CAR-T
|
|
CD74
|
LUAD
|
fusion, nrg1-fusion, immune
|
|
CD79B
|
PCNSL, DLBCLNOS
|
bcr-pathway
|
|
CD80
|
SKCM
|
T-cell, co-stimulation, immune-checkpoint, antigen-presenting
|
|
CD86
|
SKCM
|
T-cell, co-stimulation, immune-checkpoint, antigen-presenting
|
|
CD8A
|
COAD, HNSC
|
t-cell, icr-signature, immune-infiltration
|
|
CD8B
|
COAD
|
t-cell, icr-signature, immune-infiltration
|
|
CD99
|
|
|
|
CDH1
|
EGC, STAD, ESCA, GEJ
|
|
|
CDH13
|
|
|
|
CDH2
|
DESM, MEL
|
cadherin, tumor-suppressor-candidate, desmoplastic-melanoma, lof-burden
|
|
CDK12
|
PRAD, PRNE, HGSOC
|
|
|
CDK2
|
|
|
|
CDK4
|
RMS, ARMS, ERMS, ACRM
|
cell-cycle, amplification, actionable
|
|
CDK5RAP2
|
MEL
|
kinase-fusion, braf-partner
|
|
CDK6
|
GB
|
rb-pathway, cell-cycle
|
|
CDK7
|
THAP, THPA
|
|
|
CDK8
|
|
|
|
CDKAL1
|
SCLC
|
chromosomal-instability, sclc, significantly-mutated-gene
|
|
CDKN1A
|
BLCA, UTUC
|
tumor-suppressor, cell-cycle
|
|
CDKN1B
|
PRAD
|
cell-cycle, tumor-suppressor, CDK-inhibitor, prostate-cancer
|
|
CDKN2A
|
PTCL, MEITL, LUAD, NSCLC, RMS, ARMS, BLCA, UTUC, PAAD, MPNST, MFH, OS, ANGS, EGC, STAD, ESCA, GEJ, CESC, HCC, DIFG, GB, ASTR, LMS, ULMS, PLMESO, MEL, THAP, PTAD, ACRM
|
cell-cycle, tumor-suppressor, deletion, prognostic, kras-allele-specific
|
|
CDKN2B
|
NSCLC, LUAD, BLCA, UTUC, MPNST, MFH, OS, ANGS, EGC, STAD, ESCA, GEJ, RMS, ARMS, PLMESO, PTAD, THAP
|
cell-cycle, tumor-suppressor, deletion, brain-metastasis
|
|
CDKN2C
|
PCM
|
tumor-suppressor, cell-cycle
|
|
CEACAM1
|
|
|
|
CEBPA
|
|
|
|
CENPF
|
DIFG, GB, ASTR, ODG
|
|
|
CFH
|
HCC
|
|
|
CGAS
|
HGSOC
|
|
|
CHD1
|
PRAD
|
chromatin-remodeling, tumor-suppressor, prostate-cancer
|
|
CHD2
|
MNG
|
|
|
CHD3
|
PRCC
|
chromatin-remodeling, kidney-cancer, significantly-mutated-gene
|
|
CHD5
|
|
|
|
CHD6
|
BLCA
|
mutation, chromatin-remodeling
|
|
CHD7
|
ODG
|
chromatin-remodeler, stem-progenitor, oligodendroglioma, neural-development
|
|
CHD8
|
DLBCLNOS
|
chromatin-remodeling, SWI-SNF, driver, transcription
|
|
CHEK1
|
|
|
|
CHEK2
|
PRAD, PRNE
|
|
|
CHFR
|
ESCC, ESCA
|
|
|
CHGA
|
NBL
|
neuroendocrine-marker, neuroblastoma, noradrenergic, adrenergic
|
|
CHGB
|
NBL
|
neuroendocrine-marker, neuroblastoma, noradrenergic, adrenergic
|
|
CHRNA7
|
NBL
|
cholinergic-receptor, neuroblastoma, progenitor-identity, cell-of-origin
|
|
CIC
|
ODG, DIFG
|
transcriptional-repressor, oligodendroglioma
|
|
CITED1
|
|
|
|
CLCN6
|
|
|
|
CLDN11
|
NBL
|
tight-junction, neuroblastoma, progenitor-program, cell-of-origin
|
|
CLDN18
|
STAD
|
fusion, GS-subtype, cell-adhesion
|
|
CLPTM1L
|
NBL, ACRM
|
structural-variant, tert-adjacent
|
|
CLTC
|
TRCC
|
gene-fusion, TFEB, kidney-cancer, MiTF-family
|
|
CMTR2
|
LUAD
|
RNA-cap-methyltransferase, significantly-mutated-gene, lung-adenocarcinoma
|
|
CNR1
|
RMS
|
|
|
COBL
|
SCLC
|
|
|
COL14A1
|
PAAD
|
|
|
COL1A1
|
MEL
|
extracellular-matrix, fibroblast-marker, melanocyte-lineage
|
|
COL1A2
|
GBC
|
CAF, stromal, fibrosis, collagen
|
|
COL22A1
|
SCLC
|
collagen, sclc, significantly-mutated-gene, unknown-function
|
|
COL4A1
|
GBC
|
CAF, stromal, fibrosis, collagen
|
|
COL4A2
|
GBC
|
CAF, stromal, fibrosis, collagen
|
|
COL6A3
|
TNBC
|
extracellular-matrix, collagen, breast-cancer
|
|
COL8A1
|
GBC
|
CAF, stromal, fibrosis, collagen
|
|
CP
|
|
|
|
CPM
|
GBM
|
amplification
|
|
CPQ
|
PRCC
|
kidney-cancer, significantly-mutated-gene, uncharacterized
|
|
CPT1C
|
|
|
|
CRACDL
|
SCLC
|
|
|
CREB1
|
|
|
|
CREBBP
|
BLLKMT2A, MNG, LUAD
|
epigenetic-regulator, relapse
|
|
CRKL
|
ANGS
|
amplification, MAPK, sarcoma, radiation-associated
|
|
CRLF2
|
|
|
|
CRTC1
|
EPIS, SARCNOS
|
somatic-mutation, shared-ancestry, intra-patient-heterogeneity
|
|
CSDE1
|
PHC, PGNG
|
|
|
CSF1R
|
LCH, ECD
|
kinase, histiocytosis, actionable
|
|
CSMD1
|
MEL
|
tumor-suppressor, complement, melanoma
|
|
CSMD3
|
HGSOC
|
tumor-suppressor, ovarian-cancer, significantly-mutated-gene
|
|
CSNK2B
|
MB
|
kinase, WNT-pathway, medulloblastoma
|
|
CTCF
|
|
|
|
CTDNEP1
|
MB
|
tumor-suppressor, phosphatase, chromosome-17, medulloblastoma
|
|
CTLA4
|
COAD
|
immune-checkpoint, icr-signature, counter-regulation
|
|
CTNNA1
|
STAD
|
hereditary-cancer, gastric-cancer, germline, cell-adhesion, HDGC
|
|
CTNNB1
|
UCEC, UCS, HCC, NSCLC, BRCA, PAAD, MEL, PRAD, BLCA
|
|
|
CTNND1
|
STAD
|
hereditary-cancer, gastric-cancer, germline, cell-adhesion, FNHGC
|
|
CTTN
|
|
|
|
CUL1
|
|
|
|
CUL3
|
LUSC
|
|
|
CUL4A
|
OS
|
|
|
CXCL1
|
|
|
|
CXCL10
|
COAD
|
chemokine, icr-signature, immune-infiltration
|
|
CXCL16
|
|
|
|
CXCL9
|
COAD
|
chemokine, icr-signature, immune-infiltration
|
|
CYLD
|
|
|
|
CYP11B1
|
PHC, PGNG
|
|
|
CYP1A1
|
|
pharmacogenomics, AHR-target, xenobiotic-metabolism
|
|
CYP21A2
|
PHC, PGNG
|
|
|
CYP7A1
|
|
|
|
DAAM2
|
MEL
|
neural-crest, melanocyte-stem-cell, transcriptomic-marker
|
|
DAXX
|
PTAD
|
|
|
DBH
|
NBL
|
noradrenergic-marker, neuroblastoma, adrenal-gland, differentiation
|
|
DCC
|
MEL
|
tumor-suppressor, netrin-receptor, melanoma
|
|
DCLK1
|
CSCC
|
|
|
DDIT3
|
DDLS, SARCNOS
|
|
|
DDR2
|
LUSC
|
|
|
DDX1
|
CCA
|
rna-helicase, cholangiocarcinoma, immune-microenvironment
|
|
DDX3X
|
HNSC
|
RNA-helicase, apoptosis, somatic-mutation, whole-exome-sequencing
|
|
DDX41
|
ADCC
|
RNA-helicase, suspected-germline
|
|
DEK
|
PRAD, ACRM
|
copy-number, allelic-imbalance, neuroendocrine, prostate-cancer, fusion
|
|
DEPDC5
|
HCC
|
|
|
DHFR
|
BLCA
|
amplification, therapeutic-target
|
|
DICER1
|
CLLSLL
|
mirna-biogenesis, novel-driver, u-cll
|
|
DIS3
|
CLLSLL
|
novel-driver, clumps
|
|
DKK1
|
PRAD
|
WNT-pathway, EZH2-target, epigenetic-silencing, neuroendocrine, prostate-cancer
|
|
DKK2
|
|
|
|
DLC1
|
HCC
|
|
|
DLEU1
|
CLLSLL
|
|
|
DLEU2
|
CLLSLL
|
|
|
DLK1
|
SCLC
|
|
|
DLL3
|
|
|
|
DLST
|
BRCA
|
splicing-target, sf3b1-regulated
|
|
DMD
|
MNG, RMS, ARMS, ERMS
|
|
|
DNAJB1
|
FLC
|
fusion, pathognomonic, fibrolamellar
|
|
DNAJB6
|
MB
|
chaperone, fusion-gene, medulloblastoma, SHH-subgroup
|
|
DNM2
|
|
|
|
DNM3
|
ADCC
|
|
|
DNMT3A
|
PTCL, AITL
|
epigenetic-regulator
|
|
DNMT3B
|
|
|
|
DOCK2
|
|
|
|
DOCK7
|
NBL
|
migratory-marker, neuroblastoma, progenitor, adrenal-gland
|
|
DOT1L
|
STAD
|
hereditary-cancer, gastric-cancer, germline, histone-methyltransferase, epigenetics
|
|
DSCAM
|
MRT, MRTL
|
recurrent-mutation, tumor-suppressor-candidate, rhabdoid-tumor
|
|
DUX4
|
ACYC
|
homozygous-deletion, copy-number, salivary-gland, adenoid-cystic-carcinoma
|
|
DVL3
|
PHC, PGNG
|
wnt-signaling, pheochromocytoma, paraganglioma
|
|
DYRK1A
|
|
|
|
E2F1
|
BLCA
|
amplification, transcription-factor, cell-cycle
|
|
E2F3
|
BLCA
|
amplification, transcription-factor, cell-cycle, lineage-driver
|
|
EBF1
|
DLBCLNOS
|
|
|
ECT2
|
EAC
|
|
|
EDC4
|
BRCA
|
metastasis-enriched, mrna-processing, breast-cancer
|
|
EED
|
MPNST
|
|
|
EGF
|
HCC
|
|
|
EGFR
|
LUAD, LUSC, NSCLC, EGC, GBM
|
oncogene, targeted-therapy, tki-resistance
|
|
EGLN1
|
PHC, PGNG
|
hypoxia, pseudohypoxia, pheochromocytoma, paraganglioma, germline
|
|
EGR1
|
MM
|
transcription-factor, somatic-hypermutation
|
|
EGR2
|
CLL
|
|
|
EIF1AX
|
THAP
|
tumor-suppressor, thyroid
|
|
EIF2D
|
CSCC
|
|
|
ELF3
|
|
|
|
ELF4
|
|
|
|
ELK4
|
|
|
|
ELMO1
|
EAC
|
|
|
ELOC
|
CCRCC
|
|
|
EML4
|
NSCLC
|
fusion-partner
|
|
EML6
|
|
|
|
EMSY
|
BRCA
|
|
|
EN1
|
ACYC
|
MYB-target, transcription-factor, high-grade-biomarker, adenoid-cystic-carcinoma
|
|
ENOSF1
|
BRCA
|
splicing-target, sf3b1-regulated
|
|
EOMES
|
MB
|
|
|
EP300
|
|
|
|
EP400
|
BLCA
|
mutation, chromatin-remodeling
|
|
EPAS1
|
CCRCC
|
|
|
EPC1
|
PAAD
|
|
|
EPCAM
|
HCC
|
|
|
EPHA2
|
|
|
|
EPHA3
|
|
|
|
EPHA4
|
HCC
|
|
|
EPHA6
|
|
|
|
EPHA7
|
|
|
|
EPHB1
|
|
|
|
EPHB6
|
|
|
|
ERBB2
|
LUAD, OGCT, BLCA, UTUC, BRCA, NSCLC, EGC, CESC, UCEC, GBM
|
oncogene, amplification, targeted-therapy
|
|
ERBB3
|
CESC, NBL
|
receptor-tyrosine-kinase, targeted-therapy, neuroblastoma, progenitor
|
|
ERBB4
|
PLLS, MFS
|
receptor-tyrosine-kinase, oncogene, sarcoma
|
|
ERC1
|
|
|
|
ERCC2
|
BLCA
|
DNA-damage-response, DDR, cisplatin, urothelial, prognostic-biomarker
|
|
ERCC4
|
BLCA
|
|
|
ERG
|
PRAD
|
fusion, oncogene, prostate
|
|
ERRFI1
|
|
|
|
ESPL1
|
BLCA
|
mutation, chromosomal-segregation
|
|
ESR1
|
BRCA
|
endocrine-resistance, post-treatment-enrichment, breast-cancer, hormone-receptor
|
|
ESRRG
|
ACC
|
fusion, nuclear-receptor
|
|
ETS2
|
PRAD
|
transcription-factor, ETS-family, tumor-suppressor, prostate-cancer
|
|
ETV1
|
PRAD, ODG
|
transcription-factor, fusion, ETS-family, prostate, CIC-target, oligodendroglioma
|
|
ETV3
|
PRAD
|
transcription-factor, ETS-family, prostate-cancer
|
|
ETV4
|
PRAD
|
transcription-factor, fusion, ETS-family, prostate
|
|
ETV5
|
ODG
|
transcription-factor, ETS-family, CIC-target, oligodendroglioma
|
|
ETV6
|
IFS, SCSRMS
|
fusion, NTRK3, diagnostic-marker, sarcoma
|
|
EWSR1
|
|
|
|
EXO1
|
PAAD
|
|
|
EXT2
|
|
pharmacogenomics, drug-sensitivity-predictor, erlotinib
|
|
EZH1
|
MPNST
|
|
|
EZH2
|
DLBCL, FL
|
epigenetic, histone-methyltransferase, GCB
|
|
FAAH2
|
CHRCC
|
|
|
FADD
|
OSCC
|
|
|
FAM131B
|
PAST
|
|
|
FAM3C
|
MEL
|
neoantigen, immunotherapy, checkpoint-blockade, melanoma
|
|
FANCA
|
RMS, ERMS
|
dna-repair, fanconi-anemia, homologous-recombination
|
|
FANCB
|
PRAD
|
dna-repair, fanconi-anemia, homologous-recombination
|
|
FANCC
|
|
|
|
FANCD2
|
PAAD
|
|
|
FANCE
|
PRAD
|
dna-repair, fanconi-anemia, homologous-recombination
|
|
FANCF
|
THAP
|
DNA-repair, Fanconi-anemia, germline
|
|
FANCG
|
PRAD
|
dna-repair, fanconi-anemia, homologous-recombination
|
|
FANCI
|
PRAD
|
dna-repair, fanconi-anemia, homologous-recombination
|
|
FANCL
|
PRAD
|
dna-repair, fanconi-anemia, homologous-recombination, ubiquitin-ligase
|
|
FANCM
|
UCS, MXOV
|
|
|
FAP
|
|
|
|
FASN
|
CCRCC
|
|
|
FAT1
|
PTCL, THAP, CSCC
|
|
|
FAT2
|
ESCC
|
|
|
FAT3
|
HGSOC
|
tumor-suppressor, cadherin
|
|
FAT4
|
ADOCA
|
|
|
FBN1
|
MEL
|
neural-crest, melanocyte-stem-cell, transcriptomic-marker, extracellular-matrix
|
|
FBXO24
|
STAD
|
|
|
FBXO7
|
|
|
|
FBXW7
|
MNG, CESC, UCEC, RMS
|
tumor-suppressor, ubiquitin-ligase
|
|
FER
|
|
|
|
FEV
|
ES
|
|
|
FGA
|
HCC
|
|
|
FGF16
|
ADOCA
|
|
|
FGF19
|
NSCLC, LUAD
|
amplification, metastasis, FGFR, pan-cancer
|
|
FGF2
|
PAST
|
|
|
FGF3
|
HCC
|
|
|
FGF4
|
HCC
|
|
|
FGF9
|
THAP
|
growth-factor, copy-number-loss, thyroid
|
|
FGFR1
|
OS, RMS, PRAD
|
amplification, sarcoma, radiation-associated
|
|
FGFR2
|
BLCA, UTUC, PAAD
|
oncogene, receptor-tyrosine-kinase, fusion
|
|
FGFR3
|
BLCA, UTUC, EGC
|
oncogene, receptor-tyrosine-kinase, targeted-therapy, resistance, fusion
|
|
FGFR4
|
|
|
|
FGR
|
|
tyrosine-kinase, gene-fusion, promoter-swap, tcga-pancan
|
|
FH
|
PRCC, CHRCC
|
|
|
FHIT
|
MEL
|
|
|
FLCN
|
|
|
|
FLG
|
PAAD
|
|
|
FLI1
|
|
|
|
FLT1
|
|
|
|
FLT3
|
BLLKMT2A, THAP
|
kinase, signaling, sub-clonal
|
|
FLT3LG
|
MRT, MRTL
|
super-enhancer, stem-cell, differentiation
|
|
FLT4
|
ANGS
|
amplification, VEGF-signaling, MAPK, sarcoma, radiation-associated
|
|
FMN2
|
SCLC
|
|
|
FN1
|
|
|
|
FOS
|
THYM
|
|
|
FOXA1
|
LUAD, PRAD, BRCA
|
lineage-factor, metastasis
|
|
FOXA2
|
CCRCC
|
|
|
FOXD3
|
NBL
|
schwann-cell-precursor, neural-crest, neuroblastoma, stem-cell-marker
|
|
FOXM1
|
MNG
|
transcription-factor, proliferation, oncogene
|
|
FOXN4
|
MPNST
|
|
|
FOXO1
|
RMS, ARMS
|
fusion, pediatric
|
|
FOXO3
|
PRAD
|
|
|
FOXP1
|
PAAD
|
transcription-factor, forkhead, molecular-subtype
|
|
FOXP2
|
ADOCA
|
|
|
FOXP3
|
COAD, HNSC, HGSOC
|
treg, immune-signature, icr, immunotherapy, biomarker
|
|
FOXQ1
|
BLCA
|
transcription-factor, SMG
|
|
FPR1
|
SCLC
|
|
|
FRAS1
|
BRCA
|
metastasis-enriched, extracellular-matrix, breast-cancer
|
|
FRS2
|
RMS
|
amplification, FGF-signaling
|
|
FSIP1
|
DM
|
|
|
FSIP2
|
BRCA
|
metastasis-enriched, breast-cancer
|
|
FUBP1
|
CLLSLL
|
early-event
|
|
FUS
|
ES
|
|
|
FZD8
|
PHC, PGNG
|
wnt-signaling, pheochromocytoma, paraganglioma, mirna-regulation
|
|
G6PD
|
CCRCC
|
|
|
GAB2
|
|
|
|
GABRA6
|
HGSOC
|
ion-channel, GABA-receptor
|
|
GALNT7
|
EAC
|
|
|
GATA2
|
AML
|
|
|
GATA3
|
|
|
|
GATA4
|
|
|
|
GATA6
|
|
|
|
GCC2
|
BRCA
|
splicing-target, sf3b1-regulated
|
|
GEN1
|
ACC
|
DNA-repair, suspected-germline
|
|
GFAP
|
ODG
|
astrocytic-marker, glioma, lineage-differentiation, immunohistochemistry
|
|
GFI1
|
MBL
|
|
|
GFI1B
|
MBL
|
|
|
GGNBP2
|
|
|
|
GH1
|
TNBC
|
|
|
GJC1
|
NBL
|
surface-marker, extracellular-vesicle, liquid-biopsy, neuroblastoma
|
|
GLI1
|
RMS
|
transcription-factor, amplification, hedgehog-pathway, sarcoma
|
|
GLI2
|
PAAD
|
|
|
GLI3
|
PAAD
|
|
|
GLIS2
|
AMKL
|
fusion, pediatric, poor-prognosis, leukemia
|
|
GLUL
|
HCC
|
|
|
GNA11
|
MEL
|
|
|
GNA13
|
CHL
|
early-event, lymphoma-driver
|
|
GNAI1
|
PAST
|
|
|
GNAQ
|
SKCM
|
|
|
GNAS
|
APAD, PTAD, PAAD
|
oncogene, chemoresistance, molecular-subtype
|
|
GNLY
|
COAD
|
cytotoxic, icr, immune-signature
|
|
GPBAR1
|
|
|
|
GPC3
|
HCC
|
|
|
GPR149
|
|
|
|
GPS2
|
MB
|
|
|
GRB10
|
CCRCC
|
|
|
GRB7
|
BRCA
|
|
|
GREB1
|
ULMS
|
|
|
GRIN2A
|
EGC
|
|
|
GRP
|
SCLC
|
|
|
GSE1
|
MBL
|
|
|
GSK3B
|
|
|
|
GSTM1
|
STAD
|
|
|
GTF2I
|
THYM
|
|
|
GZMA
|
COAD
|
cytotoxic, icr, immune-signature
|
|
GZMB
|
COAD
|
cytotoxic, icr, immune-signature
|
|
GZMH
|
COAD
|
cytotoxic, icr, immune-signature
|
|
H1-4
|
CLL, DLBCLNOS
|
|
|
H1-5
|
|
|
|
H3-3A
|
DIFG
|
histone, epigenetic-driver, glioma
|
|
HACD1
|
|
smooth-muscle, neural-crest, transcriptomic-marker, melanocyte
|
|
HAVCR2
|
HGSOC, SKCM
|
checkpoint, exhaustion, immune-evasion, cd8-t-cell, nk-cell
|
|
HCK
|
|
|
|
HDAC2
|
PAAD
|
|
|
HECTD4
|
ACRM, SKCM
|
e3-ubiquitin-ligase, acral-melanoma, structural-variation
|
|
HECW1
|
EAC
|
ubiquitin-ligase, esophageal-adenocarcinoma, candidate-driver
|
|
HERC1
|
|
|
|
HERC2
|
|
pigmentation, uv-damage, transcriptomic-marker, melanocyte
|
|
HES1
|
SCLC
|
|
|
HGF
|
|
pharmacogenomics, met-pathway, drug-sensitivity-predictor
|
|
HIF1A
|
CCRCC
|
transcription-factor, hypoxia, VHL-pathway
|
|
HLA-A
|
HGSOC
|
immune-evasion, antigen-presentation, MHC-I, interferon-signaling, ovarian-cancer
|
|
HLA-B
|
NSCLC, LUAD
|
antigen-presentation, immune-escape
|
|
HLA-C
|
|
|
|
HLA-DPA1
|
|
mhc-class-ii, antigen-presentation, transcriptomic-marker, melanocyte, pigmentation
|
|
HLA-E
|
HGSOC
|
immune-evasion, NK-cell, MHC-I, NKG2A, non-classical-MHC, ovarian-cancer
|
|
HMCN1
|
THAP
|
cell-adhesion, tumor-invasion, anaplastic-thyroid
|
|
HMGA1
|
UCEC, ULM
|
chromatin-remodeling, enhancer-hijacking, structural-variation, endometrial-polyp
|
|
HMGA2
|
DDLS
|
|
|
HMOX1
|
|
oxidative-stress, pigmentation, uv-damage, transcriptomic-marker, melanocyte
|
|
HNF1A
|
HCC
|
|
|
HNF1B
|
CCRCC
|
transcription-factor, renal-development, HIF2A-target
|
|
HNF4A
|
CCRCC
|
transcription-factor, renal-development, HIF2A-target
|
|
HOTAIR
|
MRT
|
lncRNA, super-enhancer, hox, epigenetics
|
|
HOXA7
|
DIFG, AST
|
HOX, transcription-factor, epigenetic-target, glioma
|
|
HOXB13
|
PRAD
|
|
|
HOXD13
|
DIFG, AST
|
HOX, transcription-factor, master-regulator, epigenetic, glioma
|
|
HOXD8
|
|
|
|
HRAS
|
ANGS, CESC, RMS
|
missense, hotspot, RAS, MAPK, VEGF-signaling, sarcoma, radiation-associated, cervical-cancer, rhabdomyosarcoma, RAS-pathway
|
|
HSPA1A
|
HCC
|
|
|
HSPA5
|
|
|
|
HSPG2
|
THAP
|
cell-adhesion, extracellular-matrix, anaplastic-thyroid
|
|
HTR1F
|
|
|
|
ICOS
|
SKCM
|
|
|
IDH1
|
DIFG, AST, ODG, IHCH, GB
|
metabolic-driver, glioma, actionable, epigenetic-evolution
|
|
IDH2
|
PTCL, AITL, DIFG, AST, ODG, GB
|
metabolic-driver, glioma
|
|
IDO1
|
COAD
|
immunoregulatory, icr, immune-signature
|
|
IFITM1
|
HGSOC
|
interferon-stimulated-gene, ISG, immune-response, ovarian-cancer, IFN-signaling
|
|
IFNE
|
HGSOC
|
type-i-interferon, innate-immunity, immune-evasion, fallopian-tube
|
|
IFNG
|
COAD
|
th1, icr, immune-signature
|
|
IGF1
|
MM
|
pharmacogenomics, drug-sensitivity-predictor, growth-factor
|
|
IGF1R
|
MM, HNSC, LMS
|
pharmacogenomics, drug-sensitivity-predictor, receptor-tyrosine-kinase, targeted-therapy
|
|
IGF2
|
RMS
|
growth-factor, fusion-associated, rhabdomyosarcoma
|
|
IGF2R
|
HCC
|
|
|
IGFBP2
|
ADCA
|
IGF-axis, secreted-protein, somatic-mutation
|
|
IGFN1
|
BRCA
|
|
|
IGH
|
DLBCL
|
immunoglobulin, gene-fusion, tcga-pancan, lymphoma
|
|
IKBKB
|
OSCC, DLBCLNOS
|
NF-kB-pathway, kinase, 11q13-amplicon, HNSCC
|
|
IKZF1
|
BLL
|
|
|
IKZF2
|
BLL
|
|
|
IKZF3
|
BLL
|
|
|
IL10
|
STAD
|
|
|
IL12B
|
COAD
|
th1, icr, immune-signature
|
|
IL17RC
|
SKCM
|
|
|
IL17RD
|
ADCA
|
PI3K-inhibitor, FGFR-interaction, somatic-mutation
|
|
IL17RE
|
SKCM
|
|
|
IL1B
|
STAD
|
|
|
IL23R
|
IMT
|
|
|
IL36A
|
|
|
|
IL4R
|
CHL
|
aid-off-target, hodgkin-lymphoma
|
|
IL6R
|
HCC
|
|
|
IL6ST
|
HCC
|
|
|
IL7R
|
ESCC
|
|
|
INHBA
|
|
|
|
INO80
|
CLLSLL
|
novel-driver, chromatin-remodeler, cll
|
|
INO80D
|
RMS
|
fusion, chromatin-remodeling
|
|
INPP4A
|
|
|
|
INPP4B
|
PRAD
|
tumor-suppressor, PI3K-pathway, phosphatase
|
|
INPPL1
|
|
phosphatase, PI3K-pathway, BRAF-fusion-co-alteration
|
|
INSR
|
STAD
|
|
|
IRF1
|
COAD
|
icr-signature, immune-signature
|
|
IRF2
|
HCC
|
|
|
IRF4
|
MM, DLBCLNOS
|
transcription-factor, oncogene, hotspot
|
|
IRF6
|
HNSC
|
transcription_factor, squamous_differentiation
|
|
IRF7
|
HGSOC
|
interferon-regulatory-factor, ISG, IFN-signaling, ovarian-cancer
|
|
IRF9
|
HGSOC
|
interferon-regulatory-factor, ISG, IFN-signaling, ovarian-cancer
|
|
IRS2
|
COADREAD
|
|
|
ISG15
|
HGSOC
|
interferon-stimulated-gene, ubiquitin-like, IFN-signaling, ovarian-cancer
|
|
ISL1
|
NBL
|
noradrenergic-marker, neuroblastoma, adrenal-gland, transcription-factor
|
|
ITGAE
|
PAAD
|
|
|
ITGB1
|
|
|
|
ITK
|
|
|
|
ITM2A
|
|
melanocyte, neural-crest, transcriptomic-marker
|
|
ITPKB
|
CHL
|
hodgkin-lymphoma, aid-off-target
|
|
JAG1
|
OSCC
|
Notch-pathway, Notch-ligand, HNSCC, copy-gain
|
|
JAG2
|
OSCC
|
Notch-pathway, Notch-ligand, HNSCC, copy-gain
|
|
JAK1
|
UCEC, PRAD, COAD, SKCM
|
kinase, JAK-STAT, MSI, immunotherapy-resistance, mismatch-repair
|
|
JAK2
|
DLBCLNOS, SKCM
|
kinase, clonal-hematopoiesis, hematologic-malignancy-risk
|
|
JAK3
|
HCC
|
|
|
JAM3
|
|
|
|
JARID2
|
EAC
|
chromatin-remodeling, SWI-SNF, esophageal-adenocarcinoma, epigenetic
|
|
JAZF1
|
UCEC, ULM
|
transcription-factor, endometrial-stromal-tumor, fusion-gene
|
|
JPT1
|
HCC
|
|
|
JUN
|
DDLS
|
|
|
JUP
|
EAC
|
|
|
KANSL1
|
BLCA
|
|
|
KAT6A
|
EAC
|
acetyltransferase, chromatin-remodeling, esophageal-adenocarcinoma, candidate-driver
|
|
KAT6B
|
|
|
|
KBTBD4
|
|
|
|
KCNJ3
|
MRT
|
ion-channel, intronic-mutation, rhabdoid-tumor
|
|
KDM4B
|
STAD
|
|
|
KDM4C
|
|
|
|
KDM4D
|
|
|
|
KDM5A
|
ADCA
|
chromatin-remodeling, histone-demethylase, somatic-mutation
|
|
KDM5B
|
BLCA
|
chromatin-remodeling, histone-demethylase, somatic-mutation
|
|
KDM5C
|
KIRC
|
histone_demethylase, epigenetic_regulator
|
|
KDM5D
|
|
|
|
KDM6A
|
BLCA, UTUC, MNG, PRAD
|
tumor-suppressor, chromatin, histone-demethylase, meningioma, prostate
|
|
KDR
|
ANGS
|
amplification, gain-of-function, VEGF-signaling, sarcoma, radiation-associated
|
|
KEAP1
|
LUAD, HNSC, NSCLC
|
co-mutation, metastasis
|
|
KEL
|
GBM
|
somatic-mutation, significantly-mutated-gene
|
|
KIAA1549
|
DIFG, PAST
|
fusion-partner, glioma, BRAF-fusion, pilocytic-astrocytoma
|
|
KIF1B
|
|
|
|
KIF5B
|
|
|
|
KIT
|
OGCT, GIST, ANGS, CSCC
|
germ-cell-tumor, gist, oncogene
|
|
KLF15
|
|
|
|
KLF4
|
MNG, BLCA
|
transcription-factor, meningioma, driver
|
|
KLF5
|
BLCA
|
transcription-factor, SMG
|
|
KLF6
|
URCC
|
|
|
KLHL14
|
DLBCLNOS
|
|
|
KLHL6
|
DLBCLNOS
|
|
|
KLK3
|
PRAD
|
serine-protease, biomarker, prostate-cancer, kallikrein
|
|
KLRK1
|
HGSOC
|
NK-cell, activating-receptor, immune-surveillance, ovarian-cancer
|
|
KMT2A
|
BLLKMT2A, BLCA
|
epigenetic-regulator, histone-methyltransferase, fusion-gene
|
|
KMT2B
|
UCEC
|
epigenetic-regulator, histone-methyltransferase, endometrial-cancer, racial-disparity
|
|
KMT2C
|
CLLSLL, CESC, BLCA, EGC
|
epigenetic-regulator, m-cll, cervical-cancer
|
|
KMT2D
|
CLLSLL, ANGS, MFH, CESC, PRAD, CSCC, HNSC, DLBCLNOS, BLCA
|
epigenetic-regulator, m-cll, cervical-cancer, prostate, BRAF-fusion-co-alteration
|
|
KMT2E
|
BLCA
|
chromatin-remodeling, histone-methyltransferase, somatic-mutation
|
|
KNSTRN
|
CSCC
|
|
|
KRAS
|
LUAD, LUSC, APAD, LCH, ECD, NSCLC, PAAD, CESC, HCC, EGC, UCEC, RMS, COAD, CSCC, CHOL
|
oncogene, mapk, driver, allele-specific
|
|
KRT14
|
BLCA
|
keratinocyte-marker, cell-identity, transcriptomic-marker
|
|
KRT17
|
|
keratinocyte-marker, cell-identity, transcriptomic-marker
|
|
KRT19
|
|
|
|
KRT20
|
BLCA
|
|
|
KRT5
|
BLCA
|
keratinocyte-marker, cell-identity, transcriptomic-marker
|
|
KRT6A
|
BLCA
|
|
|
L1CAM
|
BLCA
|
|
|
LAG3
|
HGSOC
|
immune-checkpoint, T-cell-exhaustion, ICI-target
|
|
LAMA5
|
CSCC
|
|
|
LANCL2
|
GBM
|
|
|
LCK
|
SKCM
|
|
|
LDB1
|
MB
|
|
|
LGR5
|
NBL
|
stem-cell-marker, wnt-signaling, neuroblastoma, progenitor
|
|
LIF
|
MRT
|
cytokine, focal-deletion, rhabdoid-tumor
|
|
LIPA
|
|
lysosomal-enzyme, melanocyte, antigen-presentation, transcriptomic-marker
|
|
LLGL1
|
|
|
|
LMCD1
|
|
|
|
LOX
|
STAD
|
epigenetic-field-defect, promoter-methylation, gastric-cancer, H-pylori
|
|
LOXL2
|
|
|
|
LRMDA
|
UCEC, ULM
|
translocation-partner, enhancer-hijacking, endometrial-polyp
|
|
LRP1
|
ATC
|
tumor-suppressor, cell-adhesion
|
|
LRP1B
|
|
|
|
LRP2
|
|
|
|
LSAMP
|
GBM
|
|
|
LSS
|
BLCA
|
|
|
LTK
|
THPA
|
fusion, receptor-tyrosine-kinase, thyroid-cancer
|
|
LTO1
|
OSCC
|
11q13-amplicon, HNSCC, oncogene, copy-gain
|
|
LUM
|
|
fibroblast-marker, extracellular-matrix, cell-identity, transcriptomic-marker
|
|
LXN
|
BLCA
|
epigenetic-silencing, tumor-suppressor, bladder-cancer, carboxypeptidase-inhibitor
|
|
LYN
|
OSCC
|
SRC-family-kinase, HNSCC, copy-gain, kinase
|
|
LZTR1
|
GBM
|
|
|
MACF1
|
HCC
|
|
|
MACROD2
|
SKCM
|
structural-rearrangement, melanoma
|
|
MAGEA6
|
PAAD
|
|
|
MAGEB10
|
COAD
|
|
|
MAGI2
|
SKCM
|
structural-rearrangement, melanoma, PTEN-pathway
|
|
MAGI3
|
TNBC
|
scaffold_protein, PTEN_regulator, fusion_gene
|
|
MALAT1
|
BLCA
|
lncRNA, bladder-cancer, molecular-subtype
|
|
MAML1
|
HNSC
|
|
|
MAML2
|
PAAD
|
|
|
MAML3
|
PAAD
|
|
|
MAP10
|
|
|
|
MAP2K1
|
LCH, ECD
|
mapk, histiocytosis, actionable
|
|
MAP2K2
|
CLLSLL
|
mapk, novel-driver, cll
|
|
MAP2K4
|
BRCA
|
deletion, tumor-suppressor, breast-cancer, MAPK-pathway
|
|
MAP2K7
|
|
|
|
MAP3K1
|
|
mapk, sarcoma, clonal-evolution, intra-tumoral-heterogeneity
|
|
MAP3K13
|
BRCA
|
kinase, JUN_kinase_pathway, tumor_suppressor
|
|
MAP3K15
|
|
|
|
MAP3K5
|
ACYC
|
|
|
MAP3K7
|
|
|
|
MAP3K8
|
ACRM, SKCM
|
mapk-pathway, rna-fusion, acral-melanoma
|
|
MAPK1
|
BRAF-fusion, CRC
|
MAPK-pathway, kinase, co-mutation
|
|
MAPK3
|
SKCM
|
|
|
MATR3
|
UCEC, ULM
|
rna-binding, retrocopy, endometrial-polyp
|
|
MAX
|
GIST
|
myc-pathway, transcription-factor
|
|
MB21D2
|
|
|
|
MC1R
|
|
melanocyte, pigmentation, UV-response, transcriptomic-marker
|
|
MCL1
|
HGSOC
|
BCL2-family, anti-apoptotic, IFN-signaling, IRDS, chemoresistance
|
|
MCM2
|
MNG
|
proliferation, biomarker, IHC
|
|
MDM2
|
LUAD, RMS
|
p53-pathway, metastasis, amplification, ctDNA
|
|
MDM4
|
GB
|
p53-pathway
|
|
MECOM
|
HGSOC
|
oncogene, transcription-factor, amplification
|
|
MED1
|
|
|
|
MED12
|
ARMS, RMS, ULMS, UCEC
|
mediator-complex, hotspot, uterine
|
|
MED13
|
MB
|
Mediator_complex, transcription_coactivator, WNT_pathway
|
|
MEF2B
|
DLBCL, FL
|
transcription-factor, epigenetic, GCB
|
|
MEGF8
|
UCEC, GYNEC
|
hedgehog-signaling, immunotherapy-biomarker, tumor-microenvironment
|
|
MEIS1
|
MRT
|
homeobox, transcription-factor, rhabdoid-tumor, developmental
|
|
MEN1
|
PANET
|
tumor-suppressor, histone-methyltransferase, chromatin-remodeling
|
|
MEOX2
|
MRT
|
homeobox, transcription-factor, rhabdoid-tumor, bmp-signaling, differentiation
|
|
MERTK
|
|
|
|
MET
|
LUAD, NSCLC, ATC, EGC, HNSC
|
rtk, metastasis, resistance, amplification
|
|
METTL3
|
CHOL, IHCH
|
|
|
MFAP5
|
GBC
|
caf-marker, tumor-microenvironment, extracellular-matrix
|
|
MGA
|
LUAD
|
myc-pathway, metastasis
|
|
MGAT4C
|
COAD
|
|
|
MGMT
|
BRAIN, DIFG, AST, GB
|
epigenetic, methylation, chemotherapy-response, glioma
|
|
MICA
|
|
|
|
MIDN
|
TRCC
|
fusion, translocation, nccRCC
|
|
MIR15A
|
|
|
|
MIR17HG
|
RMS
|
|
|
MIR205
|
|
|
|
MIR21
|
|
|
|
MITF
|
MEL
|
melanocyte-master-regulator, transcription-factor, cell-identity, melanoma-driver
|
|
MKI67
|
ODG, NBL, HNSC
|
proliferation-marker, immunohistochemistry, flow-cytometry, single-cell
|
|
MKRN1
|
PA
|
BRAF-fusion-partner, pilocytic-astrocytoma, structural-variant
|
|
MLANA
|
MEL
|
melanocyte-marker, cell-identity, melanoma-antigen, transcriptomic-marker
|
|
MLH1
|
UCEC, PRAD, PLMESO, PITU, GB
|
mismatch-repair, MMR, MSI, immunotherapy
|
|
MLH3
|
|
mismatch-repair, MMR
|
|
MLLT10
|
AML
|
fusion, KMT2A-partner, leukemia, transcription-factor
|
|
MLLT11
|
BLCA
|
amplification, copy-number, 1q21, urothelial-carcinoma
|
|
MLLT3
|
AML
|
fusion, KMT2A-partner, leukemia, transcription-factor
|
|
MN1
|
ASTB, EWS
|
transcription-factor, fusion-gene, astroblastoma, sarcoma
|
|
MPL
|
ET, MF
|
myeloproliferative-neoplasm, JAK-STAT, thrombopoietin-receptor
|
|
MRE11
|
LUAD
|
homologous-recombination, dna-repair, lung-adenocarcinoma, never-smoker
|
|
MRPS31
|
SKCM
|
|
|
MSH2
|
UCEC, PRAD, PITU, GYNEC, GB, NSCLC
|
mismatch-repair, MMR, MSI, immunotherapy
|
|
MSH3
|
CRC, PRAD
|
mismatch-repair, MMR, BRAF-fusion, microsatellite
|
|
MSH6
|
BRAIN, PRAD, PITU, GYNEC, UCEC, GB
|
mismatch-repair, MMR, MSI, hypermutation, immunotherapy, alkylator-resistance
|
|
MSL3
|
CLLSLL
|
novel-driver, m-cll
|
|
MSMB
|
EGC
|
resistance, hypoxia, MAPK-pathway, scRNA-seq
|
|
MSRA
|
MM
|
|
|
MT1E
|
EGC
|
metallothionein, resistance, scRNA-seq
|
|
MT1H
|
EGC
|
metallothionein, resistance, scRNA-seq
|
|
MT2A
|
EGC
|
metallothionein, resistance, scRNA-seq
|
|
MTAP
|
BRCA
|
deletion, tumor-suppressor, breast-cancer, CDKN2A-locus
|
|
MTOR
|
KIRC, CSCC
|
kinase, PI3K_pathway, drug_target
|
|
MUC1
|
BLCA
|
|
|
MUC12
|
|
|
|
MUC16
|
|
|
|
MUC3A
|
|
|
|
MUC4
|
|
|
|
MUTYH
|
|
|
|
MX1
|
HGSOC
|
IFN-signaling, IRDS, innate-immunity, chemoresistance
|
|
MYB
|
BRAIN, DIFG, AST
|
transcription-factor, epigenetic, glioma, treatment-induced
|
|
MYBL1
|
ADCA
|
|
|
MYC
|
CLLSLL, LUAD, NSCLC, ANGS, MNM, CESC, DLBCL, EGC, CSCC, HNSC
|
oncogene, amplification, brain-metastasis, translocation
|
|
MYCBP2
|
BLL
|
transcriptional-regulator, B-ALL, oncogene, DUX4-ERG-subtype
|
|
MYCL
|
SCLC
|
|
|
MYCN
|
AST, DIFG, RMS, PRAD, NBL
|
oncogene, amplification, neuroendocrine, neuroblastoma, risk-stratification
|
|
MYD88
|
CLLSLL, PCNSL, DLBCLNOS, DLBCL
|
nfkb, m-cll, temporal-ordering, bcr-pathway, LymphGen
|
|
MYH11
|
AML
|
fusion, CBFB-partner, core-binding-factor, leukemia, inv16
|
|
MYL9
|
SKCM
|
myosin, neural-crest, melanocyte-state, LowMut-marker
|
|
MYLK
|
SKCM
|
myosin-kinase, neural-crest, melanocyte-state, LowMut-marker
|
|
MYO3A
|
TNBC
|
mutation, cytoskeleton, breast-cancer
|
|
MYO6
|
ACYC
|
|
|
MYOCD
|
SARC, LMS
|
amplification, leiomyosarcoma, smooth-muscle, transcription-factor, sarcoma
|
|
MYOD1
|
SCRMS, RMS
|
rhabdomyosarcoma, spindle-cell, myogenic
|
|
NACC2
|
|
|
|
NALCN
|
PAAD
|
|
|
NAPRT
|
BLCA
|
epigenetic-silencing, bladder-cancer, NAD-biosynthesis, tumor-suppressor
|
|
NAV2
|
COAD, READ
|
fusion, WNT-pathway
|
|
NAV3
|
DDLPS
|
amplification, liposarcoma, sarcoma, 12q13-15
|
|
NBN
|
|
|
|
NCAM1
|
|
|
|
NCOA1
|
RMS
|
|
|
NCOA2
|
PRAD
|
|
|
NCOA3
|
BLCA
|
transcriptional-coactivator, steroid-receptor, clonal-evolution, urothelial-carcinoma
|
|
NCOA4
|
THPD
|
fusion-gene, ret-fusion, nuclear-receptor-coactivator, thyroid-cancer
|
|
NCOR1
|
BRCA
|
deletion, transcriptional-repressor, breast-cancer, novel-candidate
|
|
NCOR2
|
RMS, FPRMS
|
transcriptional-corepressor, rhabdomyosarcoma
|
|
NDRG1
|
|
|
|
NDUFS1
|
|
|
|
NEAT1
|
BLCA
|
lncRNA, bladder-cancer, molecular-subtype, nuclear-paraspeckle
|
|
NECTIN4
|
BLCA
|
|
|
NEGR1
|
|
|
|
NEK5
|
|
|
|
NEUROD1
|
BRAIN, DIFG, AST
|
transcription-factor, epigenetic, glioma, IDH-mutant
|
|
NF1
|
LUAD, NSCLC, MPNST, ATC, RMS, UCEC, SKCM, HCC, GBM, CSCC, HNSC
|
tumor-suppressor, ras-pathway, metastasis, loss-of-function, CNA-loss
|
|
NF2
|
MNG, PLMESO, CSCC
|
tumor-suppressor, 22q-loss, merlin, meningioma
|
|
NFATC1
|
|
|
|
NFATC2
|
SARC
|
|
|
NFE2
|
MPN
|
myeloproliferative-neoplasm, transcription-factor
|
|
NFE2L2
|
LUSC, HNSC
|
|
|
NFIB
|
ODG
|
transcription-factor, stem-cell-program, glioma, progenitor
|
|
NFKB1
|
CLLSLL
|
nfkb-pathway, cll-driver
|
|
NFKBIA
|
CSCC
|
|
|
NFKBIE
|
CLLSLL, CHL
|
nfkb-pathway
|
|
NGFR
|
|
|
|
NHERF1
|
PRCC
|
tumor-suppressor, nccRCC, scaffold-protein
|
|
NIN
|
PAAD
|
MutSigCV, pancreatic-cancer
|
|
NIPBL
|
BLCA
|
|
|
NKAIN2
|
|
|
|
NKD1
|
PRAD
|
|
|
NKX2-1
|
LUAD, NSCLC
|
lineage-factor, lung
|
|
NKX3-1
|
LUAD
|
brain-metastasis
|
|
NOL10
|
PRAD
|
|
|
NOTCH1
|
CLLSLL, ATC, CSCC, HNSC
|
cll-driver, tumor-suppressor, skin-cancer, loss-of-function
|
|
NOTCH2
|
CSCC
|
tumor-suppressor, skin-cancer, Notch-pathway, loss-of-function
|
|
NOTCH3
|
MFH
|
notch-signaling
|
|
NOTCH4
|
CSCC
|
|
|
NPAS3
|
GBM
|
|
|
NPM1
|
AML
|
AML-driver, co-mutation, epigenetic-subtype, intermediate-risk
|
|
NQO1
|
|
|
|
NR0B1
|
|
|
|
NR1H4
|
CHOL, IHCH, EHCH, PHCH
|
|
|
NR3C1
|
TNBC
|
mutation, glucocorticoid-receptor, breast-cancer
|
|
NR4A3
|
|
|
|
NRAS
|
APAD, LCH, ECD, ATC, RMS, PRAD
|
ras-pathway, oncogene, hotspot
|
|
NRF1
|
PRAD
|
fusion, BRAF-partner, chromoplexy, structural-rearrangement
|
|
NRG1
|
PAAD
|
fusion, ERBB3, MAPK-WT, actionable
|
|
NRXN3
|
|
|
|
NSD1
|
AML, HNSC
|
fusion, NUP98-partner, histone-methyltransferase, leukemia, pediatric-AML
|
|
NSD2
|
MCL
|
|
|
NSD3
|
LUSC
|
|
|
NT5C2
|
BLLKMT2A
|
relapse, nucleotidase
|
|
NT5E
|
|
|
|
NTHL1
|
|
base-excision-repair, BER, germline, dMMR
|
|
NTNG1
|
SKCM
|
netrin, neural-crest, melanocyte-state, LowMut-marker
|
|
NTRK1
|
LCH, ECD, pan-cancer, NBL
|
fusion, actionable, BRAF-resistance, neuroblastoma, favorable-prognosis, neurotrophin-receptor
|
|
NTRK2
|
NBL
|
neurotrophin-receptor, neuroblastoma, poor-prognosis, cell-of-origin, progenitor
|
|
NTRK3
|
IFS, PAAD, pan-cancer
|
fusion, actionable, ETV6, larotrectinib, NTRK-inhibitor
|
|
NUAK1
|
ESCA
|
kinase, significantly-mutated, esophageal-adenocarcinoma
|
|
NUMB
|
HNSC
|
notch-pathway, copy-gain, OSCC
|
|
NUP214
|
AML
|
|
|
NUP98
|
AML
|
fusion, NSD1-partner, nucleoporin, leukemia, HOXA-activation
|
|
NUTM1
|
THYM
|
fusion, BRD4, NUT-carcinoma, thymic-carcinoma
|
|
NXF1
|
|
|
|
OLIG1
|
ODG
|
oligodendrocyte-marker, glioma, lineage-differentiation
|
|
OLIG2
|
ODG
|
oligodendrocyte-marker, glioma, lineage-differentiation, transcription-factor
|
|
OMG
|
ODG
|
oligodendrocyte-marker, glioma, lineage-differentiation, myelin
|
|
OR5L1
|
PRAD
|
olfactory_receptor, significantly_mutated_gene
|
|
OSBPL3
|
BRCA
|
metastasis, prognostic
|
|
OTX2
|
MB
|
transcription_factor, amplification, medulloblastoma
|
|
P2RY8
|
|
|
|
PABPC1
|
PAAD
|
MutSigCV, pancreatic-cancer, RNA-binding
|
|
PADI2
|
|
|
|
PAG1
|
BLL
|
hypodiploid-ALL, lymphoid-signaling
|
|
PAIP1
|
BLCA
|
|
|
PAK1
|
BRCA
|
amplification, kinase, breast-cancer, IntClust2
|
|
PAK2
|
ACRM, SKCM
|
|
|
PAK3
|
DMEL
|
|
|
PALB2
|
PAAD, BRCA
|
tumor-suppressor, BRCA-pathway, HRD, PARPi, germline
|
|
PALLD
|
SKCM
|
actin-cytoskeleton, neural-crest, melanocyte-state, LowMut-marker
|
|
PAPPA2
|
|
|
|
PARD3
|
CSCC
|
tumor-suppressor, polarity-complex, skin-cancer, loss-of-function
|
|
PARP1
|
|
|
|
PARP2
|
PRAD
|
PARPi, DNA-repair, therapeutic-target
|
|
PARP6
|
|
|
|
PARS2
|
|
fusion, notch-pathway, aminoacyl-trna-synthetase
|
|
PASK
|
LUSC
|
kinase, sex-specific, lung-squamous
|
|
PATZ1
|
SARC
|
|
|
PAX2
|
MPNST
|
developmental-transcription-factor, PRC2-target, epigenetic-repression
|
|
PAX3
|
ARMS, RMS
|
fusion, pediatric, sarcoma
|
|
PAX5
|
BLL
|
transcription-factor, b-cell-development, b-all
|
|
PAX7
|
ARMS, RMS
|
fusion, pediatric, sarcoma
|
|
PAX8
|
|
|
|
PBRM1
|
UCEC, OVT
|
chromatin-remodeling, swi-snf, tumor-suppressor
|
|
PCDH18
|
MRT
|
cell-adhesion, protocadherin, WNT-pathway
|
|
PCNA
|
DIFG, ASTR
|
dna-replication, prognostic, glioma
|
|
PDCD1
|
COAD, HNSC
|
immune-checkpoint, icr-signature, pd-1, flow-cytometry
|
|
PDCD1LG2
|
EGC
|
immune-checkpoint, pd-l2, immunotherapy, amplification
|
|
PDCD6
|
|
|
|
PDE4DIP
|
SCLC
|
|
|
PDGFA
|
PAAD
|
amplification, growth-factor, GISTIC
|
|
PDGFRA
|
AST, DIFG, GIST, ANGS, NBL
|
receptor-tyrosine-kinase, amplification, gist, mesenchymal-marker
|
|
PDGFRB
|
NBL
|
receptor-tyrosine-kinase, mesenchymal-marker, neuroblastoma
|
|
PDHB
|
CHRCC
|
metabolic-enzyme, tumor-suppressor, nccRCC, mitochondrial
|
|
PDIA3
|
COADREAD
|
antigen-processing, MHC-class-I, ER-peptide-loading, immune-escape
|
|
PDSS2
|
|
|
|
PDXDC1
|
CHRCC
|
tumor-suppressor, nccRCC, uncharacterized
|
|
PDZD2
|
ACRM, SKCM
|
|
|
PEG10
|
CRPC
|
|
|
PGD
|
|
|
|
PGR
|
UCEC
|
hormone-receptor, transcription-factor
|
|
PHF3
|
LUSC
|
amplification, lung-squamous, novel-amplification-target
|
|
PHF6
|
AML
|
epigenetic-regulator, tumor-suppressor
|
|
PHOX2A
|
NBL
|
transcription-factor, noradrenergic-marker, neuroblastoma
|
|
PHOX2B
|
NBL
|
transcription-factor, noradrenergic-marker, neuroblastoma
|
|
PICALM
|
AML
|
fusion-gene, clathrin-assembly
|
|
PIEZO2
|
UCEC, ULM
|
|
|
PIK3C2A
|
CHOL
|
pi3k-pathway
|
|
PIK3C2G
|
CHOL
|
pi3k-pathway
|
|
PIK3C3
|
|
|
|
PIK3CA
|
LUAD, LCH, ECD, OGCT, BLCA, UTUC, BRCA, NSCLC, EGC, CESC, UCEC, HCC, THAP, THPA, IHCH, EHCH, STAD, RMS, ERMS, GBM
|
pi3k-pathway, actionable, thyroid-cancer, cholangiocarcinoma, gastric-cancer
|
|
PIK3CB
|
PRAD
|
PI3K-pathway, kinase, mCRPC, actionable
|
|
PIK3CD
|
EGC, STAD, ESCA
|
pi3k-pathway, resistance, esophagogastric
|
|
PIK3CG
|
|
|
|
PIK3R1
|
ODG, DIFG, UCEC, GBM
|
pi3k-pathway
|
|
PIK3R2
|
PNET
|
pi3k-pathway
|
|
PIM1
|
|
|
|
PIM2
|
|
|
|
PINK1
|
|
neuroblastoma, germline, mitophagy
|
|
PINX1
|
MM
|
|
|
PLAG1
|
UCEC, ULM
|
|
|
PLCB3
|
UVM
|
|
|
PLCB4
|
UVM
|
|
|
PLCE1
|
STAD
|
GWAS, susceptibility-locus, gastric-cancer, low-penetrance
|
|
PLCG1
|
ANGS
|
vascular-signaling
|
|
PLK1
|
|
|
|
PLXNA1
|
PAAD
|
pancreatic-cancer, axon-guidance, semaphorin-receptor, prognosis
|
|
PLXNB1
|
ACYC
|
|
|
PLXNC1
|
GBC
|
semaphorin-receptor, tumor-microenvironment, signaling
|
|
PMEL
|
MEL, SKIN
|
melanocyte-lineage, transcriptomic-marker
|
|
PML
|
AML
|
fusion-gene, tumor-suppressor, transcription-factor
|
|
PMS2
|
UCEC, OVT, PRAD, PAAD, GB
|
mismatch-repair, mmr, lynch-syndrome, immunotherapy-biomarker, hypermutator-phenotype
|
|
PNKD
|
PRCC
|
tumor-suppressor, nccRCC, uncharacterized
|
|
PNMT
|
NBL
|
adrenergic-marker, chromaffin-differentiation, neuroblastoma
|
|
POC5
|
|
fusion, centriole, salivary-gland
|
|
POLD1
|
UCEC
|
dna-polymerase, proofreading, ultramutator
|
|
POLD2
|
BLCA
|
dna-replication, cisplatin-response, urothelial-carcinoma
|
|
POLE
|
UCEC, PRAD, COAD
|
dna-polymerase, ultramutator, immunotherapy-biomarker, tmb
|
|
POLR2A
|
MNG
|
rna-polymerase, transcription, meningioma
|
|
POT1
|
CLL
|
CLL, telomere, driver
|
|
POU2AF3
|
SARC
|
|
|
POU2F2
|
|
|
|
POU6F2
|
NBL
|
transcription-factor, progenitor-marker, neuroblastoma
|
|
PPARG
|
BLCA
|
|
|
PPARGC1A
|
|
|
|
PPM1D
|
LUAD, BRCA, PRAD
|
clonal-hematopoiesis, therapy-related
|
|
PPP1R1B
|
BRCA, LIHC
|
|
|
PPP2R1A
|
UCEC
|
pi3k-pathway, phosphatase, tumor-suppressor, endometrial
|
|
PPP2R2A
|
BRCA
|
deletion, tumor-suppressor, breast-cancer, PP2A, cell-cycle
|
|
PPP2R5A
|
CLLSLL
|
|
|
PPP3CA
|
LUAD
|
novel-SMG, lung-adenocarcinoma, calcineurin, kinase, gain-of-function
|
|
PPP6C
|
MEL
|
phosphatase, melanoma, uv-signature
|
|
PRDM1
|
PRAD
|
mutation, transcription-factor, prostate-cancer
|
|
PRDM6
|
MB
|
enhancer-hijacking, set-domain, medulloblastoma, group4, epigenetic-regulator
|
|
PRDM9
|
HNSC
|
histone-methyltransferase, recombination, hnscc
|
|
PREX2
|
SKCM
|
mutation, structural-rearrangement, amplification, melanoma, PTEN-pathway, oncogene
|
|
PRF1
|
COAD
|
cytotoxic, icr-signature
|
|
PRIM2
|
GBM
|
|
|
PRKAA1
|
STAD
|
GWAS, susceptibility-locus, gastric-cancer, low-penetrance, AMPK
|
|
PRKACA
|
PHC, PGNG
|
PKA, cAMP-signaling, kinase, adrenal
|
|
PRKACB
|
CCA
|
fusion, kinase, mapk-pathway, cholangiocarcinoma
|
|
PRKAG1
|
CHRCC
|
AMPK, metabolic-kinase, nccRCC, activating-mutation
|
|
PRKAG2
|
CHRCC
|
AMPK, metabolic-kinase, nccRCC, activating-mutation, overexpression
|
|
PRKAR1A
|
PHC, PGNG
|
PKA, cAMP-signaling, tumor-suppressor, adrenal, germline
|
|
PRKCB
|
|
|
|
PRKCD
|
PCNSL
|
PCNSL-specific, biallelic-inactivation, kinase, NF-kB
|
|
PRKCI
|
OCSC, HNSC
|
kinase, oncogene, copy-number-gain
|
|
PRKCQ
|
COADREAD
|
RAS-pathway, kinase, novel-driver, colorectal
|
|
PRKCZ
|
|
|
|
PRKD1
|
BRCA
|
|
|
PRKDC
|
|
|
|
PRKG1
|
CTCL, SS
|
|
|
PRKN
|
|
|
|
PROM1
|
NBL
|
stem-cell-marker, neuroblastoma
|
|
PRPH
|
NBL
|
intermediate-filament, neuronal-marker, neuroblastoma
|
|
PRPS2
|
|
|
|
PRRX1
|
NBL
|
transcription-factor, mesenchymal-marker, neuroblastoma
|
|
PSCA
|
STAD
|
GWAS, susceptibility-locus, gastric-cancer, low-penetrance, GPI-anchored
|
|
PTCH1
|
UCEC, OVT
|
hedgehog-pathway, tumor-suppressor, immunotherapy-biomarker
|
|
PTEN
|
LUAD, NSCLC, OS, MNG, CESC, UCEC, STLMS, ULMS, PRAD, THPA, IHCH
|
tumor-suppressor, pi3k-pathway, thyroid-cancer, cholangiocarcinoma
|
|
PTGFRN
|
SCLC
|
|
|
PTGS2
|
STAD
|
H-pylori, inflammation, gastric-carcinogenesis, epigenetic-regulation, KDM4B
|
|
PTK2
|
OCSC, HNSC
|
kinase, oncogene, copy-number-gain
|
|
PTK7
|
|
|
|
PTP4A1
|
LUSC
|
amplification, lung-squamous, phosphatase, novel-amplification-target
|
|
PTPN1
|
CHL
|
chl-driver, early-event
|
|
PTPN11
|
LCH, ECD
|
ras-pathway
|
|
PTPN3
|
HCC
|
homozygous-deletion, phosphatase, liver-cancer
|
|
PTPN5
|
|
|
|
PTPN6
|
|
|
|
PTPRB
|
ANGS
|
vascular-signaling, phosphatase
|
|
PTPRD
|
MPNST
|
phosphatase, tumor-suppressor
|
|
PTPRG
|
|
|
|
PTPRH
|
|
|
|
PTPRJ
|
|
|
|
PTPRK
|
MEL, SKCM
|
protein-tyrosine-phosphatase, TGF-beta-target, melanoma
|
|
PTPRQ
|
|
|
|
PTPRS
|
COAD
|
protein-tyrosine-phosphatase, tumor-suppressor, colorectal-cancer
|
|
PTPRT
|
OS
|
phosphatase, tumor-suppressor
|
|
PVT1
|
MB
|
lncrna, structural-variant, medulloblastoma, rearrangement
|
|
PXDNL
|
|
|
|
QKI
|
|
|
|
RAC1
|
MEL
|
ras-family, gtpase, melanoma, uv-signature
|
|
RACK1
|
CCRCC
|
|
|
RAD17
|
|
|
|
RAD21
|
AML
|
cohesin, chromatin, AML
|
|
RAD50
|
UCEC
|
DNA-repair, endometrial-cancer, RPPA
|
|
RAD51
|
SCLC
|
dna-repair, homologous-recombination, synthetic-lethality
|
|
RAD51B
|
RMS
|
homologous-recombination, DNA-repair, HRD
|
|
RAD51C
|
OV
|
|
|
RAD51D
|
|
|
|
RAD54L
|
PDTC, ATC
|
DNA-repair, homologous-recombination, helicase
|
|
RAF1
|
HCC
|
|
|
RAI14
|
ACRM, SKCM
|
|
|
RAMP3
|
|
|
|
RAN
|
|
|
|
RAP1GAP
|
THPA
|
thyroid-cancer, tumor-suppressor, ras-pathway
|
|
RARA
|
AML
|
transcription-factor, fusion, APL, AML
|
|
RASA1
|
|
|
|
RASSF1
|
STAD, NPC
|
|
|
RB1
|
HCC, THPA
|
tumor-suppressor, thyroid-cancer
|
|
RBFOX1
|
|
|
|
RBL1
|
SCLC
|
|
|
RBL2
|
SCLC
|
|
|
RBM10
|
LUAD
|
|
|
RBM12
|
COADREAD
|
RNA-processing, splicing, novel-driver, colorectal
|
|
RBM46
|
cSCC
|
|
|
RBPJ
|
ACYC
|
|
|
RBPMS
|
THPA
|
fusion, thyroid-cancer, fusion-partner, ntrk-fusion
|
|
RBX1
|
|
|
|
RECQL4
|
THAP
|
dna-repair, helicase, cancer-predisposition, thyroid
|
|
RELA
|
EPM
|
fusion, diagnostic, prognostic, NF-kB, pediatric-oncology
|
|
RET
|
NPC, THPA
|
fusion, thyroid-cancer
|
|
RFX7
|
CLLSLL
|
cll-driver, novel-driver
|
|
RGMB
|
MEL, SKIN
|
neural-crest, transcriptomic-marker, LowMut-melanocyte
|
|
RGS7
|
|
|
|
RHOA
|
DSTAD, AITL, ATLL, PTCL, STAD, BL
|
rho-gtpase, diffuse-gastric-cancer
|
|
RHOB
|
BLCA
|
rho-gtpase, tumor-suppressor, candidate-driver
|
|
RICTOR
|
LUAD, LUSC
|
mtor-pathway, resistance, ctdna
|
|
RIMS1
|
ACYC
|
|
|
RIPK1
|
CLL
|
CLL, apoptosis, cell-cycle, driver-candidate
|
|
RIPK4
|
cSCC
|
|
|
RIT1
|
ACYC
|
ras-family, gtpase
|
|
RNF130
|
PAST
|
|
|
RNF2
|
|
|
|
RNF43
|
COAD, PRAD, CESC, PAAD
|
wnt-pathway, ubiquitin-ligase, tumor-suppressor
|
|
RNGTT
|
BLL
|
mrna-capping, dux4-target, b-all
|
|
ROBO1
|
PAAD
|
pancreatic-cancer, axon-guidance, SLIT-ROBO, tumor-suppressor
|
|
ROBO2
|
PAAD
|
pancreatic-cancer, axon-guidance, SLIT-ROBO, prognosis
|
|
ROBO3
|
PAAD
|
pancreatic-cancer, axon-guidance, SLIT-ROBO, prognosis
|
|
ROR2
|
SKCM
|
mesenchymal-transition, WNT, IPRES, immunotherapy-resistance, melanoma
|
|
ROS1
|
NSCLC, PAAD
|
fusion, kinase, actionable
|
|
RP1L1
|
PAAD
|
|
|
RPL22
|
UCEC
|
ribosomal-protein, frameshift, MSI, endometrial-cancer
|
|
RPS15
|
CLLSLL
|
|
|
RPS27
|
SKCM
|
|
|
RPS6KA2
|
ACYC
|
|
|
RPS6KA3
|
HCC
|
|
|
RPS6KB1
|
OSCC, HNSCC
|
kinase, mTOR, copy-gain, mitogenic-signaling
|
|
RPTOR
|
RMS
|
mtor-complex, structural-variant, muscle-development
|
|
RRAS2
|
PRAD
|
|
|
RRM1
|
CLLSLL
|
cll-driver, novel-driver, chemotherapy-target
|
|
RSF1
|
|
|
|
RSPO2
|
COAD
|
|
|
RSPO3
|
COAD
|
|
|
RSPO4
|
DIFG, ASTR
|
wnt-pathway, epigenetic, glioma
|
|
RTTN
|
NBL
|
progenitor-marker, centrosome, neuroblastoma
|
|
RUNX1
|
|
transcription-factor, clonal-hematopoiesis, hematologic-malignancy-risk
|
|
RUNX1T1
|
AML
|
transcription-factor, fusion, AML, favorable-risk
|
|
RXRA
|
BLCA
|
nuclear-receptor, transcription-factor, ligand-binding-domain, adipogenesis
|
|
RYBP
|
PRAD
|
|
|
RYR1
|
|
|
|
RYR2
|
ACYC
|
|
|
RYR3
|
ACYC
|
|
|
S100A4
|
MEL, SKIN
|
fibroblast-marker, transcriptomic-marker
|
|
S100B
|
MNG, NBL
|
protein-marker, ihc, meningioma, schwann-cell-precursor, neuroblastoma
|
|
S1PR2
|
|
|
|
SAMHD1
|
CLL
|
CLL, immune, driver-candidate, dNTP
|
|
SBDS
|
|
|
|
SBNO2
|
TRCC
|
|
|
SCGN
|
MNG
|
protein-marker, ihc, meningioma
|
|
SCN11A
|
|
|
|
SCN8A
|
|
|
|
SCN9A
|
|
|
|
SDHA
|
GIST
|
tumor-suppressor, sdh-deficient, gist
|
|
SDHB
|
PHC, PGNG
|
tumor-suppressor, germline, pseudohypoxia, krebs-cycle
|
|
SDHC
|
BLL
|
tumor-suppressor, germline, sdh-complex, vous
|
|
SDHD
|
PHC, PGNG
|
tumor-suppressor, germline, pseudohypoxia, krebs-cycle
|
|
SEC61G
|
GBM
|
|
|
SEMA3A
|
PAAD
|
pancreatic-cancer, axon-guidance, semaphorin, prognosis, amplification
|
|
SEMA3C
|
MEL, SKIN
|
neural-crest, transcriptomic-marker, LowMut-melanocyte
|
|
SEMA3E
|
PAAD
|
pancreatic-cancer, axon-guidance, semaphorin, amplification
|
|
SEMA3G
|
|
|
|
SEMA5A
|
|
|
|
SEMA7A
|
|
|
|
SERPINB3
|
MEL
|
serine-protease-inhibitor, immune-evasion, melanoma, biomarker
|
|
SERPINB4
|
MEL
|
serine-protease-inhibitor, immune-evasion, melanoma, biomarker
|
|
SETBP1
|
AML, JMML
|
somatic, driver, myeloid
|
|
SETD1B
|
UCEC
|
histone-methyltransferase, immunotherapy-response, chromatin-remodeling
|
|
SETD2
|
PHC, PGNG
|
tumor-suppressor, somatic, histone-methyltransferase, poor-prognosis
|
|
SETDB1
|
PLMESO
|
histone-methyltransferase, tumor-suppressor, mesothelioma, genomic-near-haploidization
|
|
SF3B1
|
CLLSLL, PTAD, ACYC
|
splicing-factor, cll-driver
|
|
SFPQ
|
CCRCC
|
|
|
SGCE
|
MEL, SKIN
|
neural-crest, transcriptomic-marker, LowMut-melanocyte
|
|
SGK1
|
DLBCL, FL
|
|
|
SH2B3
|
MPN
|
|
|
SHH
|
MB
|
hedgehog-pathway, fusion-gene, medulloblastoma
|
|
SHQ1
|
PRAD
|
|
|
SIK2
|
LUAD
|
|
|
SKP1
|
|
|
|
SLC16A4
|
PAAD
|
pancreatic-cancer, transporter, metabolism
|
|
SLC45A3
|
PRAD
|
|
|
SLC5A3
|
PRCC
|
|
|
SLC6A18
|
NBL
|
|
|
SLC6A19
|
NBL
|
|
|
SLCO1B3
|
|
|
|
SLFN11
|
|
dna-damage-response, pharmacogenomics, topoisomerase-inhibitor-biomarker
|
|
SLIT1
|
|
|
|
SLIT2
|
SCLC
|
|
|
SLIT3
|
|
|
|
SLITRK6
|
|
|
|
SLX4
|
|
|
|
SMAD2
|
|
|
|
SMAD3
|
|
|
|
SMAD4
|
ESCA, ESCC, EAC
|
tumor-suppressor, somatic, tgfb-pathway, deletion
|
|
SMAD6
|
PAAD
|
|
|
SMARCA1
|
|
|
|
SMARCA2
|
RMS, ACYC
|
swi-snf, chromatin-remodeling, relapse
|
|
SMARCA4
|
MRTL, ESCA, ESCC, EAC
|
tumor-suppressor, somatic, swi-snf, chromatin-remodeling, ezh2-target
|
|
SMARCA5
|
|
|
|
SMARCB1
|
MRTL, ATRT
|
tumor-suppressor, somatic, swi-snf, chromatin-remodeling, biallelic-loss, ezh2-target
|
|
SMARCC1
|
PAAD
|
|
|
SMARCC2
|
BLL
|
somatic, swi-snf, chromatin-remodeling, fusion, tki-target
|
|
SMARCD1
|
BRCA
|
chromatin-remodeling, SWI-SNF, tumor-suppressor
|
|
SMARCE1
|
ACYC
|
|
|
SMC1A
|
AML
|
cohesin, chromatin, AML
|
|
SMC3
|
AML
|
cohesin, chromatin, AML
|
|
SMG1
|
|
|
|
SMO
|
MNG
|
hedgehog-pathway, oncogene, meningioma
|
|
SMYD3
|
GBM
|
|
|
SNAI1
|
|
|
|
SNCAIP
|
|
|
|
SND1
|
|
fusion-partner, braf-fusion
|
|
SNRPD3
|
LUAD
|
splicing, snRNP
|
|
SNX25
|
cSCC
|
|
|
SNX31
|
SKCM
|
sorting-nexin, melanoma, candidate-driver
|
|
SOCS1
|
CHL
|
jak-stat, aid-target, hodgkin-lymphoma
|
|
SOD1
|
|
|
|
SOS1
|
LUAD
|
RAS-pathway, GEF, oncogene
|
|
SOS2
|
|
|
|
SOX10
|
NBL
|
transcription-factor, schwann-cell-precursor, neural-crest, neuroblastoma
|
|
SOX11
|
ODG
|
transcription-factor, neural-stem-progenitor, glioma, cancer-stem-cell
|
|
SOX17
|
UCEC
|
transcription-factor, WNT, beta-catenin, endometrial-cancer
|
|
SOX2
|
ESCC
|
oncogene, somatic, amplification, squamous-cell, 3q-amplicon
|
|
SOX3
|
|
|
|
SOX4
|
ODG
|
transcription-factor, neural-stem-progenitor, glioma, cancer-stem-cell
|
|
SOX6
|
NBL
|
transcription-factor, progenitor-marker, neuroblastoma
|
|
SOX7
|
MM
|
transcription-factor, sox-family, deletion, candidate-tumor-suppressor
|
|
SOX9
|
ODG
|
transcription-factor, astrocytic-lineage, glioma, differentiation-marker
|
|
SP140
|
MM
|
tumor-suppressor, lymphoid-restricted, sp100-homolog, epigenetic-regulator
|
|
SPAG17
|
|
|
|
SPART
|
EAC
|
tumor-suppressor, esophageal-cancer, AA-transversion
|
|
SPATC1L
|
BLCA
|
epigenetic-silencing, bladder-cancer, tumor-suppressor-candidate, MIBC
|
|
SPDEF
|
|
|
|
SPECC1L
|
|
|
|
SPEN
|
THPA, PRAD, ACYC
|
transcription-repressor, hormone-signaling, thyroid, prostate
|
|
SPINK1
|
PRAD
|
outlier-expression, ETS-negative, prostate-cancer
|
|
SPOP
|
PRAD, THPA
|
ubiquitin-ligase, tumor-suppressor, prostate, thyroid-cancer
|
|
SPOPL
|
PRAD
|
|
|
SPRY2
|
|
ras-mapk-pathway, mek-inhibitor-biomarker, pharmacogenomics
|
|
SPTA1
|
GBM
|
|
|
SPTAN1
|
BLCA
|
cytoskeletal, SMG, bladder-cancer, MIBC
|
|
SQSTM1
|
CCRCC
|
|
|
SRC
|
OSCC, HNSCC
|
kinase, SRC-family, copy-gain, mitogenic-signaling
|
|
SRGAP2
|
|
|
|
SRGAP3
|
|
|
|
SRSF2
|
MDS
|
splicing-factor, mds-driver, megakaryocyte-dysplasia
|
|
SS18
|
SS
|
fusion-gene, sarcoma, synovial-sarcoma, t(X;18), chromatin-remodeling
|
|
SSTR2
|
PNET, PHEO, MTC, NET
|
|
|
SSX1
|
SS
|
fusion-gene, sarcoma, synovial-sarcoma, t(X;18), cancer-testis-antigen
|
|
SSX2
|
SS
|
fusion-gene, sarcoma, synovial-sarcoma, t(X;18), cancer-testis-antigen
|
|
STAC
|
|
|
|
STAG1
|
ES
|
|
|
STAG2
|
MDS
|
cohesin-complex, mds-driver, megakaryocyte-dysplasia, morphologic-biomarker
|
|
STAR
|
PHC, PGNG
|
expression-marker, cortical-admixture, adrenal-cortex
|
|
STAT1
|
COAD, HGSOC
|
immune-signature, icr, th1
|
|
STAT3
|
PTCL
|
jak-stat, t-cell-lymphoma
|
|
STAT4
|
|
|
|
STAT5B
|
BLL, TLL
|
somatic, activating-mutation, jak-stat, bcl2-target, diagnostic
|
|
STAT6
|
CHL
|
jak-stat, hodgkin-lymphoma
|
|
STING1
|
HGSOC
|
innate-immunity, cgas-sting, precursor-lesion, hgsoc
|
|
STK11
|
STAD
|
|
|
STK19
|
|
|
|
STRN
|
|
|
|
SUFU
|
MBL
|
tumor-suppressor, somatic, hedgehog-pathway, overexpression, smo-target
|
|
SUZ12
|
MPNST
|
prc2-complex, epigenetic-regulator, tumor-suppressor
|
|
SYK
|
DLBCL
|
tyrosine-kinase, b-cell-receptor-signaling, nhl-driver
|
|
SYNE1
|
HNSC
|
nuclear-envelope, hnscc
|
|
SYNE2
|
HNSC
|
nuclear-envelope, hnscc
|
|
SYP
|
|
|
|
TACC1
|
SKCM
|
centrosome, aurora-kinase, melanoma, candidate-driver
|
|
TACC3
|
BLCA, UTUC
|
fusion-partner
|
|
TAF1
|
ACYC
|
transcription-factor, tfiid-complex, basal-transcription
|
|
TAF15
|
ES
|
|
|
TAF9
|
|
|
|
TAGLN
|
SKIN
|
transcriptomic-marker, neural-crest, smooth-muscle, melanocyte
|
|
TAP1
|
HGSOC
|
antigen-presentation, interferon-response, immune-evasion, ovarian-cancer-precursor
|
|
TAP2
|
COAD
|
antigen-presentation, MHC-I, immune-evasion
|
|
TAPBP
|
COAD
|
antigen-presentation, MHC-I, immune-evasion
|
|
TBC1D3
|
PAAD
|
rab-gap, pancreatic-cystic-neoplasm
|
|
TBK1
|
HGSOC
|
cgas-sting-pathway, innate-immunity, interferon-signaling, ovarian-cancer-precursor
|
|
TBL1XR1
|
PCNSL
|
wd40-domain, btk-inhibitor-biomarker
|
|
TBR1
|
MB
|
transcription-factor, t-box, medulloblastoma, brain-development
|
|
TBX21
|
COAD
|
immune-signature, icr, th1
|
|
TBX3
|
BRCA
|
transcription-factor, T-box, stem-cell, tumor-suppressor
|
|
TCF21
|
|
|
|
TCF4
|
PHC, PGNG
|
somatic, fusion, maml3-partner, wnt-altered
|
|
TCF7
|
COAD
|
WNT-pathway, transcription-factor
|
|
TCF7L1
|
COAD, READ
|
wnt-pathway, transcription-factor, fusion-gene, colorectal-cancer
|
|
TCF7L2
|
COAD, READ
|
wnt-pathway, transcription-factor, colorectal-cancer
|
|
TCHH
|
UM
|
|
|
TEAD1
|
|
|
|
TEK
|
NPC
|
|
|
TENT5C
|
MM
|
rna-binding, poly-a-polymerase, tumor-suppressor
|
|
TERC
|
OSCC
|
telomerase-RNA, chromosomal-gain, head-and-neck
|
|
TERT
|
ESCC
|
oncogene, somatic, amplification, telomerase
|
|
TET1
|
THPA
|
dna-methylation, epigenetic, thyroid
|
|
TET2
|
AML
|
somatic, epigenetic, dna-methylation, myeloid
|
|
TET3
|
COAD
|
|
|
TFAP4
|
ACYC
|
|
|
TFE3
|
ASPS
|
somatic, fusion, diagnostic, aspscr1-fusion
|
|
TFEB
|
TRCC
|
|
|
TFEC
|
|
|
|
TGFB1
|
CCA
|
|
|
TGFBR1
|
|
|
|
TGFBR2
|
ESCC
|
tumor-suppressor, somatic, tgfb-pathway, significantly-mutated
|
|
TGFBR3
|
|
|
|
TGIF1
|
COAD
|
TGF-beta, co-repressor, transcription-factor
|
|
TH
|
NBL
|
catecholamine-synthesis, noradrenergic-marker, neuroblastoma
|
|
THADA
|
THPA
|
fusion, thyroid-cancer, gene-fusion
|
|
THSD7B
|
|
|
|
TIAM1
|
EAC
|
RAC1-GEF, invasion, esophageal
|
|
TIGIT
|
MEL
|
immune-checkpoint, co-inhibitory-receptor, immunotherapy, T-cell, NK-cell
|
|
TLN2
|
|
|
|
TLR2
|
MCL
|
toll-like-receptor, gain-of-function, microenvironment, innate-immunity
|
|
TLR4
|
EAC
|
innate-immunity, esophageal, clustered-mutations
|
|
TLX1
|
MPNST
|
|
|
TMEM106B
|
PXA
|
somatic, fusion, braf-partner, mek-target
|
|
TMEM127
|
PHC, PGNG
|
tumor-suppressor, germline, kinase-signaling, mtor-pathway
|
|
TMEM14C
|
BRCA
|
splicing-target, sf3b1-regulated
|
|
TMEM30A
|
PCNSL
|
|
|
TMEM71
|
PNET
|
|
|
TMEM87B
|
|
|
|
TMPRSS2
|
PRAD
|
fusion-partner, erg-fusion, prostate
|
|
TMSB4X
|
CHL
|
aid-target, hodgkin-lymphoma
|
|
TNF
|
STAD
|
|
|
TNFAIP3
|
CHL
|
nfkb, hodgkin-lymphoma
|
|
TNFRSF10A
|
PCNSL
|
|
|
TNFRSF14
|
DLBCL, FL
|
|
|
TNFRSF1B
|
SS, MYCF
|
|
|
TNFRSF4
|
NPC
|
|
|
TNFRSF9
|
NPC
|
|
|
TNIP2
|
BLCA
|
|
|
TNK2
|
OSCC
|
tyrosine-kinase, copy-gain, therapeutic-target, head-and-neck
|
|
TNNT2
|
OS
|
germline, acmg-secondary, cardiomyopathy, pharmacogenomic
|
|
TOP1
|
|
topoisomerase, irinotecan-target, topotecan-target, dna-repair
|
|
TOP2A
|
PNET
|
|
|
TOX
|
PCNSL
|
|
|
TP53
|
AML, PHC, PGNG, ESCC, ESCA, BRCA
|
tumor-suppressor, somatic, germline, significantly-mutated, pan-cancer
|
|
TP63
|
ESCC
|
oncogene, somatic, amplification, squamous-cell, 3q-amplicon
|
|
TP73
|
|
|
|
TPM3
|
URCC
|
|
|
TRABD
|
|
|
|
TRAF2
|
CLLSLL
|
|
|
TRAF3
|
CLLSLL
|
nfkb, structural-variant, u-cll
|
|
TRAF3IP2
|
|
|
|
TRAF7
|
MNG
|
e3-ubiquitin-ligase, oncogene, meningioma
|
|
TRIM24
|
|
fusion-partner, braf-fusion, bromodomain
|
|
TRIM28
|
|
|
|
TRIO
|
EAC
|
RAC1-GEF, invasion, esophageal
|
|
TRMT10A
|
PRAD
|
oncogene, somatic, dna-repair, brca1-scaffold, parpi-resistance, prognostic
|
|
TRPC4AP
|
RMS
|
mycn-interacting, ubiquitin-ligase, candidate-driver
|
|
TRRAP
|
MBL
|
histone-acetyltransferase, WNT-pathway, chromatin-remodeling, medulloblastoma
|
|
TSC1
|
OS, BRCA
|
tumor-suppressor, somatic, mtor-pathway, splice-site, mtor-inhibitor-target
|
|
TSC2
|
BRCA
|
tumor-suppressor, somatic, mtor-pathway, mtor-inhibitor-target, metastasis-enriched
|
|
TSHR
|
THPA
|
thyroid-cancer, hormone-receptor, differentiation
|
|
TSPAN8
|
BLCA
|
|
|
TTC28
|
|
|
|
TTK
|
|
|
|
TTN
|
UM
|
|
|
TUBD1
|
LUAD
|
focal-amplification, tubulin
|
|
TWIST1
|
SCLC
|
|
|
TWIST2
|
SKCM
|
EMT, mesenchymal-transition, immunotherapy-resistance
|
|
TXNIP
|
ACC
|
tumor-suppressor, arrestin-domain, redox, candidate-driver
|
|
TYK2
|
BRCA
|
|
|
TYRP1
|
SKIN
|
pigmentation, melanocyte-lineage, cell-identity-marker
|
|
U2AF1
|
LUAD
|
|
|
UBA7
|
|
|
|
UBE2A
|
|
|
|
UBE2QL1
|
ACRM
|
|
|
UBE4B
|
|
|
|
UBR5
|
|
|
|
UBTF
|
PHC, PGNG
|
fusion-gene, wnt-signaling, pheochromocytoma, paraganglioma
|
|
UCA1
|
BLCA
|
lncRNA, bladder-cancer, expression-subtype
|
|
UCP2
|
|
|
|
UGT1A1
|
PB
|
pharmacogenomics, germline, irinotecan, pediatric-oncology
|
|
UHRF1
|
ACC
|
ubiquitin-ligase, p53-pathway, DNA-damage-checkpoint, epigenetic-regulator, candidate-driver
|
|
UHRF2
|
|
|
|
UPK1A
|
BLCA
|
uroplakin, bladder-cancer, differentiation-marker, expression-subtype
|
|
UPK2
|
BLCA
|
uroplakin, bladder-cancer, differentiation-marker, expression-subtype
|
|
UQCRH
|
KIRC
|
mitochondria, oxidative-phosphorylation, epigenetic-silencing, metabolic-reprogramming
|
|
USF1
|
|
|
|
USH2A
|
THPA, NBL
|
cell-adhesion, recurrent-mutation, thyroid, progenitor-marker, neuroblastoma
|
|
USP10
|
PAAD
|
|
|
USP22
|
LUAD, LUSC
|
ubiquitin-protease, amplification, lung-cancer, novel-amplification-target
|
|
USP28
|
|
|
|
USP34
|
HCC
|
|
|
USP7
|
|
|
|
USP8
|
CLLSLL
|
novel-driver, u-cll
|
|
USP9X
|
BRCA
|
ubiquitin-protease, tumor-suppressor, breast-cancer
|
|
UTY
|
BLCA
|
chromatin-remodeling, histone-demethylase, Y-chromosome, bladder-cancer
|
|
VAV1
|
LUAD
|
RAS-pathway, guanine-nucleotide-exchange-factor, lung-adenocarcinoma
|
|
VAV2
|
EAC
|
RAC1-GEF, invasion, esophageal
|
|
VCAN
|
SKIN
|
extracellular-matrix, neural-crest, transcriptomic-marker, melanocyte-stem-cell
|
|
VEGFA
|
HCC, NPC, SKCM
|
|
|
VEGFC
|
SKCM
|
angiogenesis, immunosuppression, anti-PD-1-resistance, melanoma
|
|
VGLL3
|
THPA, USARC, MFS
|
transcription-factor, copy-number-gain, thyroid, hippo-pathway, sarcoma
|
|
VGLL4
|
ESCC
|
hippo-pathway, tumor-suppressor, deletion, esophageal-cancer
|
|
VHL
|
KIRC, PAAD
|
tumor-suppressor, hypoxia, ubiquitin-ligase, pancreatic-cystic-neoplasm
|
|
VIM
|
|
|
|
VOPP1
|
GBM
|
egfr-locus, 7p11, amplification, glioblastoma
|
|
VSIR
|
SKCM
|
immune-checkpoint, immunotherapy, melanoma, anti-PD-1-response
|
|
WASF2
|
|
|
|
WASHC1
|
COADREAD
|
|
|
WDR87
|
COADREAD
|
|
|
WHSC1L1
|
PRAD, LUAD
|
|
|
WNK1
|
|
|
|
WNK2
|
|
|
|
WNT11
|
PHC, PGNG
|
wnt-signaling, overexpression, pheochromocytoma, paraganglioma
|
|
WNT4
|
PHC, PGNG
|
wnt-signaling, overexpression, pheochromocytoma, paraganglioma
|
|
WNT5A
|
SKCM
|
|
|
WNT5B
|
|
|
|
WT1
|
AML
|
tumor-suppressor, transcription-factor, leukemia
|
|
WWOX
|
EAC
|
fragile-site, deletion, tumor-suppressor, esophageal-cancer
|
|
WWTR1
|
|
|
|
XIAP
|
NPC
|
|
|
XPO1
|
CHL, DLBCLNOS
|
nuclear-export, hodgkin-lymphoma, dlbcl, crispr-essential
|
|
XPO4
|
CLLSLL
|
|
|
XRCC1
|
STAD
|
|
|
XRCC3
|
|
|
|
XRCC4
|
ACYC
|
|
|
XRN1
|
|
|
|
YAP1
|
STAD
|
|
|
YEATS4
|
DDLS
|
p53-pathway, amplification, transcription-factor, liposarcoma
|
|
YES1
|
OSCC, LUAD
|
SRC-family-kinase, copy-gain, therapeutic-target, head-and-neck
|
|
YTHDF3
|
ACYC
|
|
|
YWHAZ
|
BLCA
|
bladder-cancer, copy-number-amplification, signaling
|
|
ZAP70
|
|
|
|
ZBTB16
|
PRAD
|
|
|
ZBTB7A
|
DLBCLNOS
|
transcription-factor, dlbcl, gcb-subtype, crispr-essential, tumor-suppressor
|
|
ZC3H18
|
CLLSLL
|
novel-driver, m-cll, prognosis
|
|
ZEB1
|
|
EMT, transcription-factor, CDH1-repressor, pharmacogenomics
|
|
ZEB2
|
BLL
|
|
|
ZFAT
|
DLBCLNOS
|
transcription-factor, dlbcl, prognosis, zinc-finger
|
|
ZFHX3
|
PRAD, THPA
|
transcription-factor, zinc-finger, homeobox, tumor-suppressor, prostate-cancer, thyroid-cancer
|
|
ZFP36L1
|
CLLSLL, BRCA
|
structural-variant, u-cll, notch1-regulator
|
|
ZIC1
|
|
|
|
ZIC3
|
|
|
|
ZIM2
|
PAAD
|
pancreatic-cancer, imprinting, zinc-finger
|
|
ZMAT3
|
|
|
|
ZMYM3
|
MBL
|
chromatin-remodeling, H3K4me3, KDM6A-pathway, medulloblastoma
|
|
ZMYND11
|
LUAD, LUSC
|
chromatin-reader, tumor-suppressor, lung-cancer, novel-SMG
|
|
ZNF217
|
STAD, LUAD
|
|
|
ZNF350
|
RMS
|
zinc-finger, brca1-interacting, transcriptional-repressor, candidate-driver
|
|
ZNF595
|
|
|
|
ZNF703
|
BRCA, BLCA
|
|
|
ZNF717
|
COADREAD
|
|
|
ZNF750
|
|
|
|
ZNF765
|
CHRCC
|
|
|
ZNF862
|
COADREAD
|
|
|
ZNRF3
|
HCC, PRAD
|
|
|
ZRSR2
|
|
|